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CHAPTER I
INTRODUCTION
The Global Burden of Malaria Disease
Malaria persists as a significant public health burden in tropical and subtropical regions
of the world. According to the 2019 World Malaria Report provided by the World Health
Organization (WHO), there were approximately 228 million cases and 405,000 deaths resulting
from malaria in 2018. Despite a global decrease in cases between 2010 and 2018, the rate of
decline slowed significantly between 2014 and 2018. During 2010 and 2018, global cases
declined from 71 to 57 per 1000 population at risk, however between 2014 to 2018, cases stayed
fixed at 57 per 1000 persons. The majority of cases occurred in the WHO African Region
(93%), while the remaining were in the WHO South-East Asia Region (3.4%) or the Eastern
Mediterranean Region (2.1%). The most susceptible group at risk for infection are children in
Africa under the age of 5, who accounted for 67% of deaths worldwide. (WHO, 2019).
Malaria generates an immense financial burden on both individuals, governments, and
entire societies. According to the Centers for Disease Control and Prevention (CDC), malaria is
estimated to cost $12 billion annually, and this does not account for the lost economic growth,
which likely amounts to a much higher value (CDC, 2020). It is more accurate to think of
malaria as several diseases caused by associations of biological, ecological, social, and economic
elements, rather than just a single disease. As a result of the disease’s toll on society, there
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continues to be an immediate need for realistic, cost-effective measures to combat the disease
(Oaks et al., 1991).
The Malaria-Causing Parasite Plasmodium
Plasmodium is a genus of protozoan parasites of the phylum Apicomplexa and is the
causative agent of malaria. The genus consists of hundreds of different species, five of which
infect humans, P. falciparum, P. malariae, P. vivax, P. knowlesi, and P. ovale (Miller et al.,
2002). P. falciparum is the most lethal species that infect humans. In 2018, P. falciparum
accounted for 99.7% of global cases in the WHO African Region, 50% in the South East Asia
Region, 71% in the Eastern Mediterranean Region, and 65% in the Western Pacific Region.
P. falciparum was also responsible for 94% of cases and deaths in children under 5 in Africa.
Although not as lethal as P. falciparum, P. vivax is responsible for the second most reported
cases globally. In 2018, 75% of all P. vivax cases occurred in the region of the Americas (WHO,
2019).
The Plasmodium Life Cycle
Plasmodium species have a complex life cycle (Fig. 1) that consists of successive
developmental stages (asexual and sexual) that occur in the vertebrate host and the mosquito
vector, respectively (Oaks et al., 1991). The parasite’s life cycle begins when an infected female
Anopheles mosquito takes a blood meal on a vertebrate (human) host. Upon feeding, the
mosquito releases motile sporozoites from her saliva into the host. Shortly after entering the
host, the sporozoites reach the liver where they invade hepatocytes. Each sporozoite then
generates tens of thousands of merozoites, which travel to the host bloodstream where they
invade red blood cells (RBCs). A single merozoite will develop into a RBC-schizont generating
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about 20 new merozoites. The schizont-containing RBC ruptures and releases the merozoites
back into the bloodstream, where they invade new RBCs and repeat the process. In a small
portion of infected RBCs, merozoites differentiate into sexual male and female gametocytes that
get taken up into a new mosquito vector. The gametocytes sexually reproduce, forming the
zygote. The zygote then transforms into the elongated, polarized, and motile ookinete. The
large ookinete traverses the contents of the mosquito midgut and then penetrates the peritrophic
membrane and epithelium, where it begins development into an oocyst. The oocyst matures over
a few days and eventually generates more than 10,000 motile sporozoites. The oocyst eventually
ruptures and releases the sporozoites into the insects’ hemocoel in which they immediately
migrate to and invade the salivary glands of the mosquito. The new sporozoites are transmitted
to a new human host with the next blood-feeding, thereby completing the life cycle of the
Plasmodium.

Figure 1. The Life Cycle of Plasmodium. The Plasmodium parasite life cycle consists of a
complex series of successive developmental stages that occur in the vertebrate host (human) and
the mosquito vector. (RIGHT) Asexual replication begins when an infected mosquito injects
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parasites into a vertebrate host. (LEFT) Sexual replication occurs in the mosquito following
bloodmeal of an infected vertebrate host.
The Eukaryotic Cytoskeleton
All eukaryotes, from higher-order mammals such as humans, to the protozoan parasite
Plasmodium, have highly complex cellular cytoskeleton systems that are critical for normal cell
functioning (Alberts, 2008). A eukaryotic cell cytoskeleton consists of an intricate filamentous
network composed of three major systems that collectively enable essential cellular functions,
including chromosome segregation, division, motility, support, shape, mechanical operations,
and intracellular trafficking. The three filament systems include the intermediate filaments, the
actin- or microfilament, and the microtubules, all of which assemble from distinct families of
structural proteins. Alpha- and beta-tubulin heterodimers are the building blocks that generate
microtubules, actins generate microfilaments, and filamentous intermediate filament subunits
generate intermediate filaments. Although each system has unique properties and roles, they
interact together to facilitate whole-cell functioning.
Microtubules Are Dynamic Cell Structures
Microtubules are highly dynamic cytoskeletal structures that serve critical roles in all
eukaryotic cells, including organelle transport, DNA segregation during mitosis, motility,
organization, and structure (Alberts, 2008; Bodakuntla et al., 2019). To facilitate this wide range
of functions, microtubules must assemble into distinctive structures, such as the tracks for
intracellular transport, spindles for mitosis, and the basal body and associated flagellar axoneme
in Apicomplexan parasites (Liu et al., 2016).
Microtubules are long, hollow, cylindrical structures that are universally generated from
α- and β-tubulin heterodimers and are dynamic in nature (Fig. 2). A single microtubule filament
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has a diameter of 25nm and is constructed from 13 protofilaments that laterally associate with
each other (Alberts, 2008). The tubulin building blocks of microtubules have remained mostly
unchanged over time and are even highly conserved among distantly related organisms, such as
humans and the Plasmodium berghei (P. berghei) mouse malaria parasite. α- and β-tubulin
homologs of humans and P. berghei are 83% and 88% conserved, respectively (see Appendices
D & E). Microtubule filaments rapidly grow and shrink based on cellular needs at any given
time (Alberts, 2008). The minus-end of a microtubule is associated with a microtubule
organization center (MTOC), also known as the centrioles, near the cell nucleus. The
microtubule plus-end is the site where free tubulin heterodimers are added to the growing strand,
which extends from the MTOC to the cell periphery. The rapid growth (polymerization) and
shrinking (depolymerization) of microtubules is known as dynamic instability and is a critical
function. For example, a mammalian cell must rapidly rearrange the microtubules during a
mitotic event while cell cycling to properly separate chromosomes into the daughter cells. While
microtubules in most mammalian cells possess high stability, some microtubules have been
shown to depolymerize under certain stress condition, such as cold or in the presence of a
destabilizing drug. In neurons, microtubules remain highly stable and do not undergo dynamic
instability. Early cytoskeletal studies indicated that many microtubules remain stabilized when
purifying tubulin from brain tissue, even though other microtubule strands depolymerized
(Bodakuntla et al., 2019). Similar to neuronal cells in vertebrates, microtubules in protozoan
organisms display a high degree of stability, do not undergo dynamic instability, and have
identical distribution in all cells (Liu et al., 2016).
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Figure 2. Structure and Dynamics of Microtubules. A) Microtubules are hollow, cylindrical
structures consisting of long connected strands of linked α- and β-tubulin heterodimers. B)
Microtubule dynamic instability. Microtubules transition between phases of growth (rescue) and
shrinkage (catastrophe) according to cellular conditions. The guanin-triphosphate (GTP) form of
tubulin is added to the growing plus-end of the microtubule, and guanine-diphosphate (GDP)
tubulin form causes the microtubule to dissociate. C) Eukaryotic cells under normal
physiological conditions exhibit a normal distribution of stabilized microtubules. Free tubulin
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heterodimers are added to the plus-ends (yellow plus signs) of the growing microtubule strand,
which extends to the periphery of the cell. The microtubule minus-end (yellow minus sign) is
located at the microtubule-organizing center (MTOC). D) In cells under non-physiological
conditions (i.e. cold or drug presence) microtubules destabilize (depolymerize). In this process,
tubulins are removed at the plus-end, thus shrinking the microtubule toward the minus-end near
the MTOC (bottom). Figure 2C & 2D credit: Berge et al., in prep. Figure 2B credit: image
obtained from Brown-Anderson, H., Zanic, M., Kauer, M., & Howard, J. (2013). Microtubule
dynamic instability: a new model with coupled GTP hydrolysis and multistep catastrophe.
Bioessays, 35(5), 452-461.
The Specialized Role of Subpellicular Microtubules in Plasmodium
Protozoan organisms, including the Apicomplexan parasites Plasmodium and
toxoplasmosis-causing Toxoplasma, contain an elaborate and specialized network of
subpellicular microtubules that are critical for normal cell functions, such as motility, shape, and
division (see Fig. 3 & 5). Subpellicular microtubules are built with high specificity across
different organismal species and life stages of Apicomplexans (Liu et al., 2016) and are likely
also a necessary feature to enable host-cell invasion (Tran et al., 2012). They play a major role
in enabling cellular polarity in certain life cycle stages of Apicomplexans, including the
merozoite, sporozoite, and ookinete of Plasmodium (Fig. 3). The microtubules lie just beneath
the plasma membrane on the cytosolic facing side of the parasite pellicle – a stacked structure
consisting of the inner membrane complex (IMC) and the plasma membrane (Tran et al., 2012).
The microtubules closely associate with the IMC, a double-membrane structure that also has
essential functions in cell structure and motility (Harding & Meissner, 2014). Finally, the
microtubules extend from the apical polar ring (APR) at the apex toward the posterior end of the
parasite (Tran et al., 2012).
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Figure 3. Subpellicular Microtubules are Important Structures Throughout Developmental Life
Stages of Plasmodium. The parasite subpellicular microtubules (green lines) lay directly beneath
the parasite plasma membrane and associate with the inner membrane complex (IMC). The
subpellicular microtubules are heavily involved in enabling the elongation of the parasite
structure in the merozoites as well as especially in the ookinete and sporozoites. Thus, these
microtubules may have a more significant role for cell structure of the parasite at different life
cycle stages. Note developmental stages are not drawn to scale.
Microtubules are Regulated by Microtubule Associated Proteins (MAPs)
Specialized proteins expressed in eukaryotic cells, called microtubule-associated proteins
(MAPs), bind to and regulate microtubules (Bodakuntla et al., 2019). Evolutionarily speaking,
although tubulins have stayed relatively unchanged in eukaryotes, MAPs have diverged
significantly with time (Alberts, 2008). This divergence likely was the fuel that led to the large
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variety of MAPs that are found throughout eukaryotic organisms today. Many different MAPs,
expressed in different cell types, associate with subpellicular microtubules and thus help to
enable the microtubules to take on unique structures, behaviors, and functions in cells
(Bodakuntla et al., 2019)(Fig. 4). MAPs are classified according to their function: 1) motor (or
motile) MAPs that generate movement, 2) enzymes that break or depolymerize microtubules, 3)
microtubule-nucleator MAPs, 4) plus/minus-end binding MAPs, and 5) structural MAPs. Each
type of MAP is well-defined by their function, except for the structural MAPs, which consists of
a mixed group of proteins that shares the only characteristic of microtubule binding and
microtubule stabilization. Continued investigations into structural MAPs are needed to identify
the specific functions of different structural MAPs and to devise a better classification method.
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Figure 4. Schematic Representation of the Different Ways in Which Microtubule-Associated
Proteins (MAPs) Can Bind to Microtubules, and How These Modes of Binding Influence
Structure, Behavior, and Function. A) Binding and spacing microtubules with long MAP
projection domains; B) connecting microtubules to membranes; C) protecting microtubules from
severing enzymes, and thus from disassembly; D) crosslinking different cytoskeletal elements;
E) controlling the protofilament numbers of microtubules; F) affecting the binding and motility
of motor proteins either by forming a complex with the motor or by occupying the motor path at
the microtubule surface; G) promoting microtubule bundling by neutralizing the acidic Cterminal tails of tubulin. Note that figure image and description obtained from: Bodakuntla et
al. (2019). Microtubule-Associated Proteins: Structuring the Cytoskeleton. Trends in Cell
Biology. Vol. 29, No. 10. Retrieved May 18, 2020, from
https://www.ncbi.nlm.nih.gov/pubmed/31416684
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Structural MAPs Protect Microtubules Against Destabilization
Structural MAPs bind to microtubules and protect them against destabilization, especially
in the case when a cell is exposed to a significant decrease in temperature (Delphin et al., 2012;
Dacheux et al., 2012) or a microtubule-destabilizing compound such as nocodazole (Dacheux et
al., 2012). In animal cells, when temperatures shift from 37°C to 4°C, microtubules destabilize
(Delphin et al., 2012). The exact mechanism by which cold induces microtubules to
depolymerize is still not entirely known; however, it is suggested that it could have something to
do with changes in different microtubule dynamics aspects, including an increase in catastrophe
or disappearance of rescue events (Delphin et al., 2012). Even more, it has been shown that
microtubules destabilize in a temperature-dependent manner, beginning when the temperature
drops below 20°C. To combat a significant drop in temperature, vertebrates have evolved to
express a specialized family of microtubule-stabilizing proteins, called the stable tubule only
peptide (STOP), which protects microtubules against cold (Delphin et al., 2012). STOP are
structural MAPs that were later renamed as MAP6. MAP6 is expressed in many tissues,
including heart, lung, and brain. MAP6 localizes to microtubules at 4°C to provide stabilization
and then re-localizes back to the cytosol at 37°C. It also displays a conformational change in its
microtubule binding domain during temperature shifts, indicating that the protein adapts its
structure for microtubule binding and stabilizing in cold conditions. Microtubules also
destabilize when exposed to the synthetic compound nocodazole (Dacheux et al., 2012 & 2015).
Nocodazole has a similar microtubule destabilizing mechanism to the drugs colchicine and
podophyllotoxin, whereby each compound binds to free tubulin, thus preventing the
polymerization of a microtubule strand. Another common microtubule interacting drug is Taxol,
which stabilizes microtubules against depolymerization. Taxol is used in treating some forms of
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cancer as the compound interferes with mitosis in dividing cells (Lodish et al., 2016). In
addition to stabilizing against cold, MAP6 stabilizes microtubules against nocodazole
depolymerization (Dacheux et al., 2012).
To date, many human structural MAPs have been identified to associate with and
stabilize microtubules. The first to be discovered were isolated along with microtubules during
tubulin purification methods from brain extracts (Bodakuntla et al., 2019). They were MAP1
(MAP1a), MAP2, and tau. Both MAP1 and MAP2 are of relatively high molecular weight, 331
kDa, and 199 kDa, respectively. In contrast, tau is of low molecular weight at only 44 kDa. The
molecular size of the MAPs appears to significantly affect the structural assembly of the
microtubules in which they bind. For example, while the C-terminal region of MAP2 binds to
microtubules, the N-terminus remains unbound and instead forms long projections between
neighboring microtubules. The projections lead to an increase in the distance between
microtubules. Tau, on the other hand, absent of having long projections, may link to nearby tau
proteins on neighboring microtubules, thereby pulling microtubules together, “bundling” them in
the process. Tau is a highly studied MAP that is known for stabilizing microtubules and
controlling intracellular traffic in neuronal axons. When tau undergoes certain post-translational
modifications, it can restrict its ability to bind to microtubules, ultimately leading to the
development of intraneuronal neurofibrillary tangles (NFT) and Alzheimer’s disease
(AD)(Congdon and Sigurdsson, 2018). The absence of tau binding to axonemal microtubules is
largely associated with the development of AD (Kadavath et al., 2015).

13
MAPs in Protozoan Organisms
Like neuronal cells in humans, microtubules in protozoan organisms are highly stable, do
not undergo dynamic instability, and are resistant to depolymerization by cold or certain drug
compounds because of associations with and regulation by a myriad of structural MAPs (Liu et
al., 2016). The protozoan parasites Plasmodium, Toxoplasma, and the flagellated Sleeping
sickness-causing parasite Trypanosoma, express structural MAPs that are essential for the
regulation of the specialized subpellicular microtubules (Tran et al., 2012). This MAP regulation
is especially necessary for the large, polarized, invasive ookinete stage of Plasmodium (Fig. 5).

Figure 5. Subpellicular Microtubules in Plasmodium are Regulated by Microtubule-associated
Proteins (MAPs). Subpellicular microtubules are located just beneath the plasma membrane of
the ookinete (shown in the figure) and enable the polarized, elongated shape. They are in close
contact with the inner-membrane complex. A) Microtubule-associated proteins (MAPs) decorate
subpellicular microtubules and provide microtubule regulation. B) Cross-section of ookinete
with subpellicular microtubules (green) closely associating with the inner-membrane complex
(yellow). Image credit: Berge et al., in prep.
In Trypanosoma, the highly complex flagellum structure is vital for motion and invasion
into host cells and contains approximately 100 subpellicular microtubules that are remarkably
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stable and resistant to both cold and nocodazole. The first MAP6-like protein to be identified in
the Trypanosoma brucei (T. brucei) is called the STOP axonemal protein (TbSAXO). SAXO is
a large group of MAP6-like proteins that are present only in ciliated or flagellated organisms.
SAXO is expressed not only in T. brucei but also in the sperm of humans and flagellated
gametocytes of Plasmodium (Dacheux et al., 2012).
In the Toxoplasma gondii (T. gondii) parasite, the few structural MAPs that have been
identified to date each display a unique localization to specific subsets or subregions of
subpellicular microtubules in the parasite, suggesting that each MAP has unique properties (Liu
et al., 2016). The first structural MAP to be identified in Apicomplexans was identified in T.
gondii and was called TgSPM1 (Tran et al., 2012). TgSPM1 belongs to the SAXO family of
MAPs and was shown to decorate the entire length of the subpellicular microtubules in the
parasite (Tran et al., 2012 & Liu et al., 2013). Plasmodium contains an SPM1 homolog, called
PbSPM1 (referred to as PbSAXO1). Another structural MAP identified in previous T. gondii
studies was called Thioredoxin-like associated protein 1 (TgTRXL1). TgTRXL1 was found to
also bind to the entire length of subpellicular microtubules, but only in the presence of TgSPM1,
suggesting indirect binding. TgTRXL1 was used as bait in previous coimmunoprecipitation
experiments to identify additional structural MAPs expressed in the parasite. The new MAPs
were named TgTRXL2 (a homolog of TgTRXL1) and Trxl1-like associated proteins (TLAPs 14). Although TgTRXL2 binds to microtubules when ectopically expressed in the parasite (Liu et
al., 2013), Plasmodium does not contain the homologous MAP, nor do Plasmodium spp. contain
TLAP4. TgTLAP1 was also found to bind to microtubules when ectopically expressed in the
parasite (Liu et al., 2013). More recent investigations into TgTRXL1 and TgTLAPs 2-4
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indicated that only mEmerald-tagged TgTLAP2 showed binding to microtubules when expressed
in mammalian cells. In addition, TgTLAP2 displayed a high degree of microtubule bundling and
an intricate microtubule co-localization pattern when expressed in the parasite. Curiously, the
overexpression of TLAP2 in T. gondii causes major malformations in the structure of the
subpellicular microtubules.
TLAP2 is conserved only among some distantly related Apicomplexan parasites,
including all Plasmodium species (Liu et al., 2016). Ectopically expressed P. falciparum TLAP2
(PfTLAP2) showed potential microtubule binding when expressed in the T. gondii parasite (Liu
et al., 2016). Because PfTLAP2 is the only structural MAP that has been studied in the
Plasmodium spp., our lab decided to begin investigating SAXO, TRXL1, and TLAP2 in P.
berghei.
Preliminary Studies
Before our lab began investigations into known structural MAPs found in Plasmodium,
our lab primarily studied the thioredoxin (trx) antioxidant defense system and its potential targets
in the parasite. We first identified the P. berghei TRXL1 (PbTRXL1) (David et al., in prep), that
is conserved across Apicomplexans and was a potentially redox-active protein; however, we later
discovered that PbTRXL1 showed very low levels of reactive oxygen species (ROS) reduction
and therefore could not be classified as an antioxidant enzyme (David et al., in prep). Recently,
we considered the possibility that PbTRXL1 may play a role in the regulation of the Plasmodium
cytoskeleton considering the T. gondii researchers showed that the TgTRXL1 homolog
associated with microtubules (Liu et al., 2013). In addition, we previously revealed that the
highest level of pbtrxl1 transcript was expressed in the ookinete, which depends highly on
subpellicular microtubules for elongation (David et al., in prep).
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As students in our lab had already begun investigations into the function of PbSAXO and
PbTRXL1, I set out to investigate PbTLAP2 for my thesis research. My hypothesis was
PbTLAP2 binds to and stabilizes microtubules, thus suggesting that it is a structural MAP
that may play an important role in the regulation of the parasite microtubule cytoskeleton.
To test my hypothesis, I established a heterologous expression system consisting of human
cancer cells in our lab and generated multiple reporter expression plasmids to express PbTLAP2
in those cells for analysis of protien subcellular localization. I also generated a CRISPR/Cas9mediated gene deletion plasmid for PbTLAP2, so that our lab could determine if any phenotypes
result in TLAP2-null P. berghei parasites. I began my thesis research by generating the
CRISPR/Cas9 deletion plasmid. Generating the plasmid turned out to be a very lengthy and
challenging task. Due to time constraints, I transitioned my thesis work to the heterologous
expression system to begin investigations into microtubule binding and stabilization by
PbTLAP2.
CRISPR/Cas9-mediated Gene Deletion
The deletion or modification of a gene is a good beginning point to study gene function.
The CRISPR/Cas9 gene-editing system is a recently discovered method for efficient and
effective editing or deletion or modification of virtually any gene in any organism. The method
is derived from a naturally occurring defense mechanism consisting of Clustered Regularly
Interspaced Short Palindromic Repeats (CRISPR) occurring in bacteria. Bacteria utilize CRISPR
to sever the genomic material of invading viruses for protection. The CRISPR/Cas9 system was
developed into a technology that could be used to efficiently edit or delete a gene via an RNAdirected endonuclease, Cas9. The Cas9 protein is co-transcribed with a short guide RNA

17
(sgRNA), which together target and cause a double-stranded break (DSB) at the target location
in a chromosome. Following the DSB in the DNA, DNA repair is initiated and carried out by
either non-homologous end joining (NHEJ) or homology-directed repair (HDR)(Zhang et al.,
2014).
The CRISPR/Cas9 system has been used recently to successfully initiate deletions of
various genes in different Plasmodium species (Wagner et al., 2014 and Zhang et al., 2014). Our
lab recently generated two different P. berghei gene deletion lines, one for spm1 and the other
for trxl1 via the CRISPR/Cas9 system (Kiernan, 2017). This was the first time that
CRISPR/Cas9 has been used to generate deletions in the P. berghei species. As another
approach to investigating tlap2 function in P. berghei, I generated a CRISPR/Cas9-mediated
plasmid for the targeted deletion of the gene.
Thesis Objective
Our understanding of the Plasmodium microtubule cytoskeleton and associating proteins
is minimal at best. Subsequently, there is a need for novel research into the basic biology of the
parasite. The objective of this project was to establish a heterologous expression system for the
Plasmodium berghei novel tlap2 gene as well as generate a gene deletion plasmid for pbtlap2, to
investigate the function of the gene. The results of this thesis shed light on the makeup and
regulation of the cytoskeleton and associating proteins in the Plasmodium parasite. These data
have the potential to inform novel malaria interventions based on targeting the parasite
cytoskeleton.

CHAPTER II
MATERIALS AND METHODS
Reagents
All primers, oligos, restriction enzymes and corresponding buffers were obtained from
ThermoFisher Scientific (Waltham, MA).
Amresco; Solon, OH: glycerol, sodium dodecyl sulfate (SDS), tris.
Bioexpress; Kaysville, UT: agar, 10X phosphate-buffered saline (PBS), molecular grade water,
fetal bovine serum (FBS), tryptone.
GoldBio; St. Louis, MO: ampicillin (sodium) solution, kanamycin monosulfate solution.
Growcells.com; Irvine, CA: X-Gal Powder.
Lonza; Basel, Switzerland: Nucleofector transfection kit T, 7.5% sodium bicarbonate.
PolyPlus Transfection, Illkirch, France: JetPRIME transfection kit, JetOPTIMUS transfection
kPromega; Madison, WI: JM109 chemically competent E. coli cells, pGEM-T Easy Vector
System.
Sigma-Aldrich; St. Louis, MO: ethylenediaminetetraacetic acid (EDTA), Giemsa stain, Heparin
sodium salt, paraformaldehyde, penicillin-streptomycin, phenylhydrazine, pyrimethamine,
RPMI-1640 medium, Nycodenz, Triton X-100, Tween-20, Dulbecco’s Modified Eagle’s
Medium (DMEM).
Southern Biotech; Birmingham, AL: DAPI Fluoromount-G.
ThermoFisher Scientific; Waltham, MA: 6X DNA loading dye, Alexa Fluor 488 goat anti-rabbit
IgG, Alexa Fluor 555 goat anti-mouse IgG, Alexa bovine serum albumin (BSA), dimethyl
sulfoxide (DMSO), ethidium bromide solution, GoTaqG2 PCR master mix, hydrochloric acid
(HCl), isopropyl-β-D-thiogalactopyranoside (IPTG), GeneJet Gel Purification Kit, GeneJet PCR
Purification Kit, GeneJet Plasmid Miniprep Kit, GeneJet Whole Blood Genomic DNA
Purification Kit, GeneRuler 1kb Plus DNA Ladder, magnesium chloride (MgCl2), methanol,
mouse anti-tubulin IgG (Invitrogen), potassium phosphate (KH2PO4), rabbit anti-GFP polyclonal
IgG (Invitrogen), sodium chloride (NaCl), sodium hydroxide (NaOH), sodium phosphate
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(Na2PO4), TopVision Agarose, TOPO TA Cloning Kit with pCR4-TOPO Vector and One Shot
Top10 chemically competent E. coli cells, yeast extract.
Buffers, Media, and Solutions
1X Phosphate-buffered saline (1X PBS): Add 1 part 10X PBS to 9 parts molecular grade water,
mix, and sterile filter.
10X TAE electrophoresis buffer: 48.4g Tris base, 11.4mL glacial acetic acid, 3.7g EDTA, BTV
1L with deionized water.
10X TBE electrophoresis buffer: 108g Tris base, 55g boric acid, 40mL 0.5M EDTA (pH 8.0),
BTV 1L with deionized water.
50X TAE electrophoresis buffer: 242g Tris base, 57.1mL glacial acetic acid, 100mL
0.5M EDTA (pH 8.0), BTV 1L with deionized water.
Blocking buffer: 5% bovine serum albumin (BSA) in PBS, sterile filter.
Freezing medium – 30% glycerol (bacterial stocks): 15mL glycerol, 5mL 10X PBS, 20mL
molecular grade water, filter sterilized.
Luria-Bertani (LB) medium: 10g NaCl, 10g tryptone, 5g yeast extract, BTV 1L with deionized
water, sterilize by autoclaving.
Mammalian cell culture medium: Dulbecco’s Modified Eagle’s Medium (DMEM): 13.4g
DMEM powder, 49.3mL sodium bicarbonate (7.5%), 10mL penicillin/streptomycin, BTV 1L
with molecular grade water, filter sterilize, pH 7.4.
Pyrimethamine solution (7mg/mL): 70mg pyrimethamine, 10mL DMSO. Dissolve
by vortexing. Dilute with 100 times amount with tap water to a final volume of
1L. Adjust pH to 3.5-5. Store at 4°C for up to one week.
Schizont culture medium: RPMI-1640, 20% FBS, 1% pen-strep, pH 7.3, filter sterilize.
Equipment
Olympus; Shinjuku, Tokyo, Japan: Fluoview FV1000 confocal laser scanning microscope.
Zeiss; Oberkochen, Germany: LSM800 confocal laser scanning microscope
Gene Accession Numbers
General information regarding the genes investigated in this research is documented on
the Plasmodium Genomics Resource Database (Plasmodb.org). The accession number for the P.
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berghei tlap2 (pbtlap2) gene is PBANKA_0518100 and P. berghei saxo (pbsaxo) gene is
PBANKA_0810700. Note that the pbsaxo gene is referred to as P.berghei Subpellicular
Microtubule-Associated Protein 1 (PbSPM1) on PlasmoDB. I will refer to the gene and protein
product as pbsaxo and PbSAXO throughout this thesis.
Polymerase Chain Reactions (PCR)
Polymerase Chain Reactions (PCR) were set up using GoTaq G2 Master Mix (1X), ~1ug
DNA template, 10uM forward primer, 10uM reverse primer, and water to a final volume of
25uL/Rxn. The primer annealing temperature was set to 5°C below the melting temperature of
the primer set and the PCR elongation time was set to one minute per kilobase of DNA sequence
for all PCR reactions. The Eppendorf Mastercycler ep gradient S thermal cycler was used with
the following protocol:
▪

95°C – 5 min (initial dsDNA denaturation)

▪

95°C – 30 sec (dsDNA denaturation)

▪

55°C – 45 sec (primer annealing)

▪

64°C – 1 min/kb (fragment elongation)

▪

74°C – 5 min (final elongation)

35 cycles

PCR primers used to amplify the fragments for generation of the CRISPR/Cas9 gene
deletion plasmid and/or primers used to sequence verify the final plasmid are listed in Table 1.
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Table 1. PCR Primers for Generating CRISPR/Cas9-mediated Gene Deletion Plasmid.
The PCR primers used to amplify the gene of interest when generating expression
plasmids for mammalian cells or primers to sequence and verify expression plasmids are listed in
Table 2. Following all PCR reactions, amplified fragments were run out on an agarose gel
followed by purification of the amplicon using the GeneJet PCR Purification Kit.
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Table 2. PCR Primers for Generating Expression Plasmids for Mammalian Cells.
Restriction Digestion
All restriction enzyme digests were performed following the manufacturer
recommended conditions and in the recommended buffer for each enzyme. The desired
gene fragment used to generate each expression plasmid for the mammalian cell work was
obtained using the corresponding restrictions enzyme sets listed in Table 3.
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Table 3. Restriction Enzymes for Generating Expression Plasmids for Mammalian Cells.

All fragments digested out for generation of the CRISPR/Cas9 gene deletion construct
were obtained using the corresponding restriction enzymes listed in Table 4.

Table 4. Restriction Enzymes for Generating CRISPR/Cas9-mediated Deletion Plasmid.
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DNA Gel Electrophoresis
PCR reactions and/or DNA digests were run out on a 0.8-1.2% agarose gel in 1X TAE or
1X TBE buffer at 110 volts for 30 minutes in the Owl Horizontal Electrophoresis System
(Thermo Fisher Scientific; Waltham, MA). Each gel was prepared with 0.5ug/mL ethidium
bromide for visualization of DNA under UV light. If samples did not already contain gel
running dye, a 6X loading dye was added to the sample to a final concentration of 1X before
running the gel. The GeneRuler 1kb Plus DNA Ladder was used as a size standard for all gel
runs. All DNA fragments run out on a given gel were excised from the gel using scalpels,
followed by a purification step using the GeneJet Gel Purification Kit.
TA Cloning PCR Amplificons into Bacterial Propagation Plasmids
PCR amplified and then gel purified DNA fragments were cloned into either the pGEM
or pCR4-TOPO propagation plasmids via TA cloning methods. The ligation reactions for the
pGEM plasmid system were set up as follows: 1X Rapid Ligation Buffer, 50ng pGEM-T
plasmid, 5X more DNA fragment concentration than vector, and to a final volume of 10uL. The
ligation reactions for the TOPO vector system were set up as follows: 50-500ng DNA fragment,
10ng TOPO vector, salt solution (1.2M NaCl, 0.06M MgCl2) to a final volume of 10uL. All
ligation reactions were incubated overnight at 4°C.
Transformation of JM109 and One Shot TOP10 E. coli Competent Cells
Following ligation of PCR amplified fragments into the propagation plasmids, bacterial
transformation into either JM109 or One Shot TOP10 chemically competent E. coli cells was
performed. 1-2uL of ligation reactions was added to 25-50uL of briefly thawed competent cells.
The mixture gently mixed and incubated on ice for 20 minutes. After 20 minutes, the mixture
was heat-shocked at 42°C for 45 seconds and then immediately returned to the ice for 2 minutes.
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900uL of LB media was added to the cell mixture followed by a one-hour incubation in a shaker
incubator (225rpm) at 37°C. Transformed cells were then plated on pre-warmed LB agar plates
containing either 0.1mg/mL ampicillin or kanamycin antibiotic resistance, 20ug/mL X-gal, and
0.1mM IPTG. The addition of X-gal and/or IPTG allowed for the selection of correctly ligated
plasmids in bacteria colonies by blue/white colony screening.
Plasmid Purification
Successfully transformed white bacteria colonies were picked from agar plates and grown
in 5mL LB media containing 0.5mg ampicillin or kanamycin. The bacterial cultures were grown
overnight at 37°C in a shaker incubator at 225rpm. Following incubation, bacteria cells were
pelleted from a total of 4mL of culture by centrifugation at 6,000g for 2 minutes. Plasmids were
purified from the bacteria cells using the GeneJet Plasmid Miniprep Kit and following the
manufacturer’s protocol. Purified plasmids were eluted in 35uL of molecular grade water.
Characterization of PbTLAP2 Using Human Cancer Cells as an Expression System
To investigate the function of the novel PbTLAP2 protein, I utilized human cancer cells
as a model system to express and study the protein. I primarily used Human epithelial
osteosarcoma (U-2 OS) cells to look into whether PbTLAP2 binds to and/or stabilizes
microtubules in the cell line. In order to express the protein in U-2 OS cells, I first needed to
generate expression plasmids.
Generation of Expression Plasmids for Human Cells
Pbtlap2 full length (pbtlap2-FL), pbtlap2Δ, and/or pbsaxo open reading frames (orf’s)
were PCR amplified from P. berghei wildtype (PbWT) genomic DNA using corresponding
primers listed in Table 2. Then, the PCR amplicons were inserted into pGEM (see protocol on
TA cloning above), restriction digested out of pGEM and gel purified, and subsequently inserted

26
into the pC22-mEmerald-TgTLAP2 plasmid template. Alternatively, prepared gene fragments
were inserted into the pcDNA3.1-TbSaxo-Myc/stop-GFP expression plasmid template following
the same cloning methods.
To generate the N-terminal mEmerald-tagged pC22-mEmerald-PbTlap2-FL expression
plasmid (referred to as PL1), an 1,809 bp fragment consisting of the complete orf of pbtlap2 was
PCR amplified to contain the Kpn2I and AflII enzyme restriction sites at either end of the gene.
The gene fragment was subsequently inserted into the pC22-mEmerald-TgTlap2 plasmid
template at Kpn2I and AflII enzyme restriction sites. The plasmid template was first digested
with the same restriction enzymes to release the tgtlap2 gene. To generate the N-terminally
tagged pC22-mEmerald-PbTlap2Δ plasmid (PL2), a 774 bp fragment consisting of a truncated
version of the pbtlap2 gene was inserted into the same plasmid template and following the same
methods. To generate the N-terminally tagged pC22-mEmerald-PbSaxo plasmid (PL7), a 999 bp
fragment consisting of the complete orf of the pbsaxo gene was inserted into the same plasmid
template and following the same methods, however the BgIII restriction enzyme site was used in
place of the KpnI enzyme site.
For the generation of the C-terminal GFP-tagged expression plasmids, I used the same
cloning methods as previously described; however, the KpnI and XbaI restriction enzymes sites
were used in place of the Kpn2I and AflII restriction sites. The pbtlap2-F (1,806 bp), pbtlap2Δ
(771 bp), and pbsaxo (999 bp) amplicons were PCR amplified to include the corresponding
restriction enzyme sites and subsequently cloned into the pcDNA3.1-TbSaxo-Myc/stop-GFP
plasmid template. Note, digesting the pcDNA3.1-TbSaxo-Myc/stop-GFP plasmid template with
the KpnI and XbaI enzymes removed from the plasmid a 168 bp sequence coding for the Myc
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tag immediately followed by a stop codon. This allowed for the insertion of the corresponding
gene of interest, which would subsequently be fused with GFP, rather than Myc, following
translation in cells. Thus, to generate the pcDNA3.1-PbTlap2-FL-GFP (PL3), pcDNA3.1PbTlap2Δ-GFP (PL4), and pcDNA3.1-PbSaxo-GFP (PL8) expression plasmids, the
corresponding PCR amplicons were cloned into the digested plasmid template at the KpnI and
XbaI restriction enzyme sites.
To generate the C-terminal Myc-tagged expression plasmids, I utilized the previously
generated C-terminal GFP expression plasmids at a template. All that was needed was to digest
the PL3, PL4, and PL8 plasmids with XbaI to linearize the plasmid. Subsequently, the
previously digested and gel purified Myc/stop fragment was inserted into either PL3, PL4, and/or
PL8 at the XbaI restriction enzyme site. The resulting plasmids were named pcDNA3.1PbTlap2-FL-Myc (PL5), pcDNA3.1-PbTlap2Δ-Myc (PL6), and pcDNA3.1-PbSaxo-Myc (PL9).
All generated expression plasmids were transformed into JM109 competent cells and purified
using the GeneJet Miniprep Plasmid Purification Kit.
For reference, all generated expression plasmids are shown in Appendix A.
Preparation and Maintenance of Human Cell System
Hela and U-2 OS cells were established in our lab and used for all expression plasmid
transfections and cell treatments. Cells were cultured in DMEM complete medium containing
10% fetal bovine serum (FBS) and 1% penicillin/streptomycin and incubated at 37°C with 5%
CO2. Cells were split with 0.05% Trypsin as necessary for maintenance or cell passaging. Initial
work in this thesis included the use of HeLa cells as our lab was already culturing these cells.
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Shortly after beginning work with HeLa cells, I acquired a new cell line, U-2 OS, and
subsequently used these cells for the remaining studies.
Transfection of Plasmids into Cells
U-2 OS cells were seeded in a Millicell EX 8-well chamber slide and allowed to grow to
~80% confluency overnight. Previously generated expression plasmids were transiently
transfected into the U-2 OS cells by using either the PolyPlus JetPRIME or JetOPTIMUS
transfection kits and following the manufacturer’s recommended protocol. Approximately
500ng of plasmid DNA was added to 50uL of transfection buffer in an Eppendorf tube followed
by brief vortexing. 1uL of transfection reagent was added to the transfection mixture and briefly
vortexed before a 10-minute incubation at room temperature. During incubation, the U-2 OS
medium in the chamber slide was discarded and replaced with 500uL of fresh complete medium.
30uL of the transfection mix was gently added to each well of U-2 OS cells. The cells were
incubated with the transfection mix for 4 hours at 37°C. After 4 hours, transfection mix/media
was replaced with fresh complete medium and cells were incubated an additional 20 hours.
Cold Treatment of U-2 OS Cells
U-2 OS cells were cold-treated 24 hours post-transfection by adding pre-chilled 4°C
complete medium and incubating at 4°C for 30 minutes. After treatment, the media was
discarded, and the cells were immediately fixed by incubation in 4% PFA for 10 minutes at room
temperature.
Nocodazole Treatment of U-2 OS Cells
U-2 OS cells were nocodazole-treated 24 hours post-transfection by adding complete
media supplemented with 20uM nocodazole to cells and incubating at 37°C for 30 minutes.
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After treatment, the media was discarded, and the cells were immediately fixed by incubation in
4% PFA for 10 minutes at room temperature.
Immunofluorescence Labeling
Firstly, transfected or non-transfected and fixed HeLa or U-2 OS cells were
permeabilized in 0.1% Triton-X 100 in PBS and incubated for 10 minutes at room temp. Cells
were the washed 3 times in 1X PBS. To block non-specific antibody binding, blocking buffer
(5% BSA in 1X PBS) was added and incubated for 60 minutes at room temp. For antibody
labeling, cells were first incubated with primary antibodies (see below for specific antibodies)
diluted in antibody buffer (1% BSA in 1X PBS) for 1 hr. Following primary antibody
incubation, cells were washed 3 times in PBS. Cells were then incubated with secondary
antibodies diluted in antibody buffer for 1 hr at room temp in the dark. Following incubation in
secondary antibodies, cells were again washed 3 times and finally mounted with DAPI
Fluoromount-G Mounting Media.
Primary antibodies: rabbit polyclonal anti-GFP IgG, 1:2000, (gifted by Dr. Jennifer
Mierisch, Loyola University Chicago, Dept. of Biology) (#TP401), Torrey Pines Biolabs,
Houston, TX; rabbit polyclonal anti-GFP IgG, 1:500 (#A-6455) Thermo Scientific, Waltham,
MA; mouse monoclonal anti-tubulin IgG, 1:500 (#236-10501); rabbit polyclonal anti-Myc IgG
1:100 (#PA1-981) Thermo Scientific.
Secondary antibodies: goat polyclonal anti-rabbit IgG AlexaFluor 488, 1:500 (#A11034)
Thermo Scientific; goat polyclonal anti-mouse IgG AlexaFluor 555, 1:500 (#A21424) Thermo
Scientific; rabbit polyclonal anti-mouse IgG AlexaFluor 488, 1:500 (#A11059) Thermo
Scientific.
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Animal Ethics Statement
All animal experiments described herein followed the National Institutes of Health
guidelines relating to the proper care/housing of animals. Also, all protocols were approved by
the Institutional Animal Care and Use Committee (IACUC) at Loyola University Chicago.
Construction of CRISPR/Cas9 Gene Deletion Plasmid for pbtlap2
The CRISPR/Cas9 gene deletion plasmid for pbtlap2 was generated using the pBCS
(Plasmodium for berghei containing Cas9) plasmid as a template, which was previously
generated by a graduate student in our lab (Kiernan, 2017). A 20nt target sequence (TS) for the
pbtlap2 gene was selected with the help of ChopChop (http://chopchop.cbu.uib.no/, Labun et al.,
2019). Primers were designed to PCR amplify the pbtlap2 TS along with a scaffold RNA
sequence in one fragment (Table 2), which would subsequently be called the guide RNA
(gRNA). Thus, the forward primer to amplify the gRNA fragment was designed with the 20 nt
TS and immediately following a 5’ NGG 3’ sequence (protospacer adjacent motif = PAM). The
forward primer included the recognition site for the NdeI restriction enzyme. The reverse primer
included the AatII restriction enzyme site as well as the 3’ end of the scaffold RNA. Thus, when
amplified, the entire gRNA fragment was 116 bp following PCR amplification. Following PCR
amplification, the gRNA was subsequently inserted into the pGEM propagation plasmid. Once
cloned into pGEM, the gRNA fragment was then digested out, gel purified, and cloned into the
pBCS plasmid template at the NdeI and AatII restriction sites. Prior to cloning the pbtlap2
gRNA into the plasmid template, pBCS was digested with NdeI and AatII to release the
endogenous pbsaxo gRNA sequence.
To generate targeted pbtlap2 gene deletion, a homology-directed repair (HDR) template
(referred to as Homology Repair Template) was generated and cloned into the generated pBCS
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plasmid which already contained the pblap2 gRNA region. Primers were designed to amplify
the 5’ untranslated region (UTR) and 3’UTR region flanking the pbtlap2 gene (Table 2). Each
region was PCR amplified using PbWT gDNA as a template. Both regions were then inserted
into a TOPO propagation plasmid that was previously generated (Kiernan, 2017) to include a
short disrupter sequence (Dis). The 5’UTR and 3’UTR regions were inserted into the plasmid so
that each flanked one side of the Dis sequence. The 5’ UTR region was first inserted at the
BamHI restriction site and the 3’ UTR region was inserted at XbaI, completing the generation of
the 5’UTR-Dis-3’UTR homology repair template. Subsequently, the homology repair template
was digested out of the TOPO plasmid at the HindIII restriction enzyme sites and inserted into
the generated pBCS plasmid with the pbtlap2 gRNA at the same restriction enzyme sites. This
completed the generation of the pbtlap2 gene deletion plasmid. I named the plasmid pBCTP2
(plasmid for berghei containing Cas9 for Tlap2 KO).
Generation of Transgenic Parasites
To generate transgenic P. berghei parasites, the pBCTP2 plasmid was transfected into P.
berghei ANKA wildtype (WT) parasites following previously established methods (Janse et al.,
2006).
Schizont Culture and Purification
A naïve mouse was infected by intraperitoneal injection with cryopreserved PbWT
parasites. The parasitemia of the mouse was monitored for several days until reaching 5-15%.
Four additional naïve mice were then infected by IP injection using 10uL of tail blood in
heparin-containing PBS from the previously infected mouse. The four mice reached a
parasitemia of 1-3% before being exsanguinated by cardiac puncture to collect a total of 2-4mL
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of PbWT infected blood. The blood was immediately added to 5mL RPMI complete medium
containing heparin. The infected red blood cells (RBCs) were harvested by centrifugation for 8
minutes at 450xg. The pelleted RBCs were resuspended in 50mL of complete medium. The
resuspended RBCs were the distributed equally among two sterile 250mL cell culture flasks and
an additional 50mL complete medium was added to each for a total of 100mL per flask. The
cultures were incubated overnight at 36.5°C to allow for the production of matured schizonts.
Once 70-80% of the schizonts reached maturity (8-12 merozoites per cell) in culture, the
100mL total culture suspension was distributed equally among three 50mL conical tubes (~33mL
per tube). Using a serological pipet, 10mL of a 17% nycodenz-PBS solution was gently added to
each tube under the culture suspension and centrifuged for 20 minutes at 450xg. Using a Pasteur
pipet, the brownish layer of purified schizonts was carefully collected from each 50mL tube and
added to a single collection tube containing fresh complete medium. The schizonts were
harvested by centrifugation for 8 minutes at 450xg. The pelleted cells were gently resuspended
in 1mL complete medium. An additional 6mL of complete medium was added to the
resuspended cells and distributed equally among seven Eppendorf tubes (1mL per tube).
Transfection of Parasites
Linearized pBCTP2 plasmid DNA was transfected into purified P. berghei schizonts by
using the Nucleofector kit T (VCA-1002; Lonza, MD). One of the Eppendorf tubes containing
schizonts was briefly centrifuged for 5 seconds at 17,000xg. The pelleted cells were resuspended
in 100uL of Nucleofector solution containing 5-10ug plasmid. The cell suspension was
transferred to an electroporation cuvette and immediately placed into the Amaxa Nucleofector II
electroporator device (Amaxa Biosystems; Cologne, Germany). The cells were electroporated
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using the U33 program. Immediately after electroporation, 50uL complete medium was added to
the cell suspension. A naïve mouse was placed under a heat lamp for 5 minutes prior to tail vein
injection to increase the diameter and visibility of the veins. The 150uL of cell suspension was
then immediately injected into the tail vein of one naïve mouse with an insulin syringe. The
entire transfection process was repeated using the remaining 6 tubes of purified schizonts.
Drug Selection
Tail vein injected mice were monitored daily for successful infection and increasing of
parasitemia. Once parasites were observed in an infected mouse, the mice were given
pyrimethamine in their drinking water to select for successfully transfected parasites. The
pBCTP2 plasmid contains a pyrimethamine resistance gene, dhfr, thus only parasites that were
successfully transfected and contain the pBCTP2 plasmid will survive during pyrimethamine
selection. Approximately 10-15 days post-injection, pyrimethamine-resistant parasites were
observed in mouse blood.
Parasite Genomic DNA Purification
Blood from infected mice under pyrimethamine selection was collected by
exsanguination. The transfected P. berghei gDNA was then purified using the GeneJet Whole
Blood Purification Kit.
Verification of Gene Deletion Parasites
Successful deletion of pbtlap2 in transfected parasites was verified by PCR. Special
primers were designed to amplify a large segment of DNA upstream and downstream of the
pbtlap2 gene. Each primer was located far enough outside of the homology repair region that
was generated to avoid cross reactivity issues with pBCT.

CHAPTER III
RESULTS
Plasmodium berghei Model System
I investigated the novel protein TRXL1-like associated protein 2 (TLAP2) of the malaria
parasite Plasmodium. Our lab uses the rodent parasite species Plasmodium berghei (P. berghei),
which is an established model organism for studies of malaria in mice and mosquitoes. P.
berghei represents a good model system for the human disease as some life cycle and
morphological characteristics, specifically those for the transmission stage in the mosquito, are
similar to the human parasite P. falciparum (Sinden et al., 1978).
Genomic Organization and Conservation of tlap2
P. berghei tlap2 (pbtlap2; PlasmoDB accession number PBANKA_0518100.1) is a
single exon gene found on chromosome 5: 657588 – 659384 of the P. berghei genome
(PlasmoDB.org). The gene consists of 1,797 bp and codes for a protein (PbTLAP2) of 598
amino acids (aa’s) (Fig. 6). The protein has a calculated molecular weight of 70.5 kDa and an
isoelectric point of 10.11. Based on information obtained from researchers studying a TLAP2
homolog in the Toxoplasma gondii apicomplexan parasite (TgTLAP2)(Liu et al., 2016), in which
they found that the C-terminal 276 amino acids (aa’s) of TgTLAP2 were able to bind to
microtubules in T. gondii, I hypothesized that the same region of PbTLAP2 (aa’s 347-597) also
bind to microtubules. If confirmed, this would indicate that the specific microtubule-binding

34

35
domain of PbTLAP2 is located within the 347-597 aa’s of the protein.

Figure 6. Organization of pbtlap2. The pbtlap2 gene consists of a single exon and is 1,797bp in
length (top). The gene codes for a 598 amino acid protein with a hypothetical microtubule
binding domain located in the C-terminal half (amino acids 347-597) of the protein (bottom).
To determine the conservation of the TLAP2 protein, an NCBI blastp search was
performed using the PbTLAP2 complete coding region as well as a separate blast using the Cterminal 347-597 aa’s search criteria. The results showed that TLAP2 is unique to apicomplexan
parasites, including Plasmodium and Toxoplasma, with the exception of a couple types of
bacteria that are clear outliers (Fig. 7). There are no other significant matches in other
organisms, including humans. Thus, TLAP2 is a novel, putative microtubule-associated protein
(MAP) unique to apicomplexan parasites, including Plasmodium and Toxoplasma, among few
others.
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Figure 7. Conservation of TLAP2 in Apicomplexa. Phylogenetic analysis of TLAP2 protein
homologs in Apicomplexa. TLAP2 protein complete coding sequence and C-terminal 347-597
amino acid (hypothetical microtubule binding domain) regions were blasted (blastp vs. refseq
protein database)(e-value >1.0) and sequence matches were identified in both blast results. Cterminus sequence retrieved from NCBI. Proteins shown in bold and italicized have a full-length
protein match. Proteins non-bold/non-italicized have match in C-terminal region only. PbTLAP2
(green box), PfTLAP2 (red box), and TgTLAP2 (red box) are highlighted. Phylogenetic tree
generated by Dr. Catherine Putonti, Bioinformatics/Biology dept. of Loyola University Chicago.
To compare the identities of the PbTLAP2 and TgTLAP2 (ToxoDB accession number
TGGT1_232130) protein homologs, I first setup a Clustal Omega multiple sequence alignment
using the complete coding sequence of each protein (Fig. 8). Initial observations of the
alignment indicate that there is no significant conservation in the N-terminus of each protein;
however, there is higher conservation in the C-terminal region. The percent identity between the
entire sequence of each protein is 12% (similarity 22%).
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Figure 8. Alignment of PbTLAP2 and TgTLAP2 homologs. Higher conservation region of
TLAP2 found within the C-terminal ~200 amin acids. The precent identity between each entire
protein sequence is 12% (similarity 22%). (gray box = similar amino acid; black box = identical
amino acid).
Considering TLAP2 appear to be somewhat conserved in the C-terminal region, I
generated another Clustal Omega sequence alignment, this time however using only the C-
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terminus of PbTLAP2 and TgTLAP2 (See Appendix B). The specific aa sequences of each
homolog that I compared was PbTLAP2 347-598 and TgTLAP2 181-456. Emboss Needle
scoring of the alignment indicated PbTLAP2 and TgTLAP2 share 26.5% identity (52.3%
similarity) in this region. In addition, I generated an alignment of the N-terminal regions
(PbTLAP2 1-346 and TgTLAP2 1-180) of each protein (See Appendix C). Scoring indicated
that the proteins share 1.6% identity (2% similarity) in the N-terminus.
Expression Profile Data of TLAP2 in Plasmodium
Transcriptome data available on PlasmoDB indicated that pltlap2 is expressed at higher
levels in the ookinete and gametocyte stages (Hoeijmakers et al., 2014) compared to other stages.
In addition, it was also shown that the gene is expressed higher in the female gametocyte
compared to male gametocyte (Yeoh et al., 2017). These findings indicate that the gene is likely
expressed higher in the mosquito stages of the parasite life cycle. Similarly, the Plasmodium
falciparum tlap2 gene from the human parasite is expressed highly in the ookinete and
gametocytes (López-Barragán et al., 2011) and higher in the female gametocyte than male
(Lasonder et al., 2016). These findings indicate that the gene is likely expressed overall higher
in the mosquito stages than the blood stages of the parasite life cycle. A previous tlap2 gene
deletion in P. berghei indicated that the gene is dispensable in the asexual stages of the parasite
(Bushell et al., 2017). For reference, a comparison of the properties of pbtlap2, pftlap2, and
Toxoplasma gondii tlap2 and their corresponding protein products, as well as expression data, is
outlined in Table 5.
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Table 5. Comparison of Plasmodium berghei, Plasmodium falciparum, and Toxoplasma gondii
tlap2 genes and protein products. Data retrieved from PlasmoDB database (Plasmodb.org).
Investigations into the Novel P. berghei TLAP2 Protein
As the function of the putative MAP, TLAP2, had not yet been studied in Plasmodium
spp. prior to this study, I began investigations into characterizing the function of PbTLAP2. For
my investigations, I considered three parallel experimental approaches: 1) expression and
purification of recombinant PbTLAP2, 2) using CRISPR to edit the pbtlap2 gene out of the P.
berghei genome and generating a pbtlap2-knock out parasite strain, and 3) establishing a
heterologous expression system that allows me to study potential PbTLAP2 microtubule-binding
in human cancer cells. This last approach was imperative as we did not yet know if the putative
MAP does in fact associate with and potentially regulate microtubules.
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First, I attempted recombinant PbTLAP2 protein expression and purification from
bacterial cells. It was my goal to investigate the potential biochemical activity of PbTLAP2
and/or its structure. Due to time constraints, I only briefly began this work and then shifted to
other experimental work. Thus, I have not included details of this work in this thesis. Next, I
generated a CRISPR/Cas9-mediated gene deletion plasmid for PbTLAP2 with the goal to
generate tlap2 gene deletion P. berghei parasites. I completed the construction of the
CRISPR/Cas9 plasmid and started initial attempts to generate the gene deletion in parasites.
Initial results will be presented in the second part of this thesis. Finally, my main project was to
express PbTLAP2 in human cancer cells (heterlogous expression system) to study potential
microtubule-binding or -stabilizing properties. The majority of my research results will illustrate
my findings on the function of PbTLAP2 by uilizing the heterologous expression system for
investigations.
Investigating PbTLAP2 Microtubule-Binding Function in a Human Cancer Cell Line
Prior studies of TgTLAP2 showed that this protein does bind to microtubules, thus
confirming it as a MAP (Liu et al., 2016). Based on this finding and because PbTLAP2 and
TgTLAP2 are somewhat conserved in their C-terminal regions containing the hypothetical
microtubule-binding domain, I hypothesized that PbTLAP2 is a MAP that binds to microtubules.
To test my hypothesis, I first adapted methods by the TgTLAP2 researchers by expressing
mEmerald-tagged PbTLAP2 in HeLa cells to investigate whether the protein would bind to
microtubules in this cell line. For this study, I was kindly gifted a plasmid from Dr. Ke Hu at the
Department of Biology, Indiana University Bloomington, to use as a template for cloning and
generation of the PbTLAP2 construct.

41
In a review of a different paper, in which researchers studied a MAP found in the
sleeping sickness-causing flagellated parasite Trypanosoma brucei (T. brucei) (Dacheux et al.,
2012), I learned that they also used human cancer cells, specifically human epithelial
osteosarcoma (U-2 OS), to express the parasite MAP with a C-terminal GFP tag for their
investigations. Subsequently, as another approach to investigating the function of PbTLAP2, I
considered using this cell line and also a different protein tag approach for my work. Following
an inquiry to these researchers, I was kindly gifted an additional expression plasmid to use for
expression of C-terminal GFP-tagged PbTLAP2 in human cancer cells.
As previously mentioned, I began my initial investigations into whether PbTLAP2 would
bind to microtubules in human cancer cells. Thus, I started my work using HeLa cells, which
our lab already had available for use. Initial investigations resulted in suboptimal results
following plasmid transfection and expression of mEmerald-tagged PbTLAP2 in these cells.
Subsequently, we were gifted a stock of U-2 OS cells from Dr. Nancy Zeleznik-Le at the
Department of Cancer Biology, Loyola’s Stritch School of Medicine (SSOM), to try as an
alternative cell line for this work. I obtained better results when transfecting and expressing the
fusion protein in this cell line, thus the remaining of my experiments were performed using U-2
OS cells and I discontinued use of the HeLa cells.
Mammalian Cell Cultures and Immunolabeling of Microtubules
Although the previous researchers had already shown that a Toxoplasma and
Trypanosoma parasite MAP could bind to microtubules in human cells, I wanted to confirm that
PbTLAP2 should also do the same in human cancer cells. To do this, I generated a sequence
alignment of the P. berghei and human alpha and beta tubulin proteins. The alignment indicated
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83% identity (See Appendix D) and 88% identity, respectively (See Appendix E). This high
conservation of the tubulin proteins between P.berghei and humans suggests that the PbTLAP2
protein should likely interact with microtubules in human cells.
Before my initial transfection and attempt at expression of mEmerald-PbTLAP2 fusion
protein in HeLa cells, I first established and confirmed my immunofluorescence (IF) methods by
immunolabeling microtubules in HeLa cells (Fig. 9-A). HeLa cells were seeded at ~80,000 cells
per well and fixed in PFA. Cellular microtubules were fluorescently labeled with primary anti-αtubulin and secondary AlexaFluor-488 conjugated antibodies. Subsequent images were captured
with a laser scanning confocal microscope. Results showed clear labeling of microtubules in all
HeLa cells, which was indicated by the appearance of green fluorescent fibers radiating from the
centrosome – or microtubule organization center (MTOC) – outward to the periphery of a cell.
Although the U-2 OS cell expression work was carried out following the HeLa cell microtubule
labeling and initial attempts as PbTLAP2 expression experiments, the results of microtubule
labeling in U-2 OS cells is shown along with the results of the HeLa cell microtubule labeling
(Fig. 9-B). The same IF methods were used to label microtubules in U-2 OS cells as was
performed with HeLa cells; however, a new confocal microscope (Zeiss) was used to capture
images of the U-2 OS cells, which allowed me to show the stained nuclei as well. With the
success of the IF methods and showing that I could fluorescently stain microtubules in the cells, I
next moved onto generation of the expression plasmid for PbTLAP2.
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Figure 9. HeLa and U-2 OS Cell Microtubule Labeling via immunostaining, A) Middle image
shows microtubules labeled in HeLa cells (green) with monoclonal anti-α-tubulin antibody. Far
left image shows zoomed in HeLa cell with MTOC, nucleus (N), and microtubules clearly
visible. B) Far right image shows microtubules labeled in U-2 OS cells (red) using the same
primary antibody, however a different secondary antibody conjugated with an AlexaFluor 555
tag. Nuclei stained with DAPI (blue).
Generation of mEmerald-PbTLAP2 Full Length Expression Plasmid
I generated a plasmid to express the complete coding sequence of PbTLAP2 (referred to
as PbTLAP2 full length or PbTLAP2-FL) fused with an N-terminal mEmerald tag. For
generation of this plasmid, I modified the plasmid template received from Dr. Ke Hu (Liu et al.,
2016)(see Fig. 12). The 6,070 bp plasmid template is referred to as pC22-mEmerald-TgTlap2
and contains an N-terminal mEmerald (720bp) fluorescent reporter tag that preceded the
TgTLAP2 gene. A highly efficient human cytomegalovirus (CMV) promoter drives the
expression of the TgTLAP2 gene in human cells. To construct the expression plasmid for
PbTLAP2-FL, I performed a series of molecular cloning steps to replace the tgtlap2 gene with
the pbtlap2 gene. First, I amplified the gene from genomic P. berghei DNA using polymerase
chain reaction (PCR). PCR primers were designed to amplify the complete coding sequence of
pbtlap2 (Table 1, P12 & P13). The forward primer included a short 9 bp coding sequence that
preceded the 5’ end of the pbtlap2 gene. This 9 bp sequence codes for a 3 amino acid linker
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(Serine, Glycine, Leucine = SGL) that connects the mEmerald and PbTLAP2 proteins during
translation. The forward primer also contains a Kpn2I restriction site necessary and the reverse
primer contained an AflII restriction site for replacement of tgtlap2 with pbtlap2. The purified
fragment was cloned into the pGEM plasmid and sequenced. The pbtlap2 gene was then
digested back out of the cloning plasmid with the Kpn2I and AflII enzymes. Simultaneously, the
pC22-mEmerald-TgTlap2 plasmid was digested with the same enzymes to remove the tgtlap2
gene along with SGL. Subsequently, the SGL-pbtlap2 fragment was inserted into the predigested template plasmid. The resulting plasmid contains the pbtlap2-FL gene and is 6,490 bp
in size. It was subsequently named pC22-mEmerald-PbTlap2-FL and for simplicity was
abbreviated to PL1.
Generation of mEmerald-PbSAXO Expression Plasmid
In addition to the PL1 plasmid, I generated a plasmid (Fig. 10) for a novel, putative MAP,
called P. berghei STOP Axonemal Protein (PbSAXO), that our lab had previously began
studying. The investigation into whether this putative MAP binds to microtubules was included
in my thesis investigation of PbTLAP2 as a side investigation. In prior studies, we investigated
the biochemical function of PbSAXO and we recently began investigating a potential connection
of PbSAXO to the cytoskeleton. Sequence alignment and analysis revealed that that PbSAXO is
indeed a MAP6-like protein and related to the SAXO family of microtubule-stabilizing proteins.
The PbSAXO protein contains several identical repeat domains that supposedly bind to
microtubules (Schaefer et al., in prep). To generate the expression plasmid for PbSAXO, I used
the same methods used previously to generate PL1. The resulting plasmid was named pC22mEmerald-PbSaxo (PL7).
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Figure 10. Plasmid Map of pC22-mEmerald-TgTlap2 Template and Generation of N-terminal
mEmerald-tagged pC22-mEmerald-PbTLAP2-FL and pC22-mEmerald-PbSaxo Expression
Plasmids. A) Generated plasmid map showing all necessary components of the expression
plasmid template, pC22-mEmerald-TgTlap2. Plasmid template contains the TgTLAP2 coding
sequence (TgTLAP2 CDS), a CMV promoter driving expression of the mEmerald-TgTLAP2
fusion protein and a kanamycin (Kan) and neomycin (Neo) resistance gene. There is also a
bacterial origin of replication (Ori) present for cloning purposes. Plasmid figure created using
SnapGene . B) Cloning of pC22-mEmerald-PbTlap2 full length (FL) expression plasmid by
replacing tgtlap2 gene sequence in pC22-mEmerald-TgTlap2 template with pbtlap2-FL gene
(1,813bp) containing a preceding Serine-Glycine-Leucine (SGL) linker sequence. Cloning by
restriction digestion at Kpn2I and AflII restriction sites. C) Translated N-terminal tagged
mEmerald-PbTLAP2-FL fusion protein. D) Cloning of pC22-mEmerald-PbSaxo expression
plasmid by replacing tgtlap2 gene sequence in same template with pbsaxo gene (1,003bp)
containing a preceding Serine-Glycine-Leucine (SGL) linker sequence. Cloning by restriction
digestion at Kpn2I and AflII restriction sites. E) Translated N-terminal tagged mEmeraldPbSAXO fusion protein.
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Transfection of U-2 OS Cells and Immunofluorescence Labeling
The PL1 plasmid was transfected into U-2 OS cells and subcellular localization of
expressed mEmerald-PbTLAP2-FL protein was tracked using IF and confocal microscopy (Fig.
11). U-2 OS cells were seeded at ~80% confluency on a Millipore chamber slide. The PL1
plasmid was transfected into confluent U-2 OS cells using the PolyPlus JetPRIME transfection
kit. Cells were fixed with PFA. Primary rabbit anti-GFP and secondary AlexaFluor-488
fluorescently conjugated antibodies were used to detect the mEmerald tag of the fusion protein.
In cells successfully transfected and expressing the mEmerald-PbTLAP2 fusion protein, a
resulting green fluorescent network, resembling the microtubules, would be expected in cells in
where the protein localized to microtubules. In contrast, cells where the fusion protein is not
localized to the microtubules should result in a diffuse green fluorescence throughout the cytosol.
To track the quality of the transfection, the efficiency following each transfection was calculated
by counting the number of cells that appeared to be successfully transfected and expressing the
MAP. The number of transfected cells were counted within a ~130µm2 field of view (FOV).
This resulting number was divided by the total number of cells in that FOV to obtain the
transfection efficiency.
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Figure 11. Transfection of Mammalian Cells with Generated Expression Plasmid,
Immunolabeling, and Subcellular Localization Analysis. A) U-2 OS cells seeded on 8-well
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chamber slide. B) Generated expression plasmid transfected into cells using liposomal chemical
transfection method. Translation of GFP-tagged fusion protein co-localizing with microtubules
in cells. C) Immunolabeling of microtubules using primary anti-tubulin antibody and
fluorescently conjugated AlexaFluor-555 secondary antibody. Labeling of GFP-tagged protein
using anti-GFP primary antibody and fluorescently conjugated AlexaFluor-488 secondary
antibody. D) Analysis of the subcellular localization of expressed microtubule-associated protein
in cells. Co-localization of protein with microtubules (left) or diffuse cytosolic distribution
throughout the cell (right).
mEmerald-PbTLAP2-FL Shows Diffuse Cytoplasmic Distribution in Cells
U-2 OS cells transfected with the pC22-mEmerald-TgTLAP2 (positive control) plasmid
and expressing the mEmerald-TgTLAP2 showed binding of the protein to microtubules (Fig. 12A). I observed a fluorescent green radiating network running throughout expressing cells, which
resembled the microtubule network and confirmed microtubule binding. In addition, when
merging fluorescence images of fluorescently labeled tubulin (red) and mEmerald-TgTLAP2
(green), a resulting yellow overlap occurred in some cells, which also confirmed binding. In
addition to microtubule co-localization, the TgTLAP2 control also appeared to induce bundle
formation, as observed by higher intensity green fluorescence over the fluorescing microtubules.
This likely was caused by concentrated areas of neighboring microtubules that were pulled
together by TgTLAP2. Interestingly, the concentration of TgTLAP2 microtubule-binding was
likely high enough to cause the binding epitope recognized by the tubulin antibody to become
blocked, thereby preventing anti-tubulin from properly binding. Both microtubule binding and
bundling findings were consistent with results from previous investigations of TgTLAP2
expressed in HeLa cells (Liu et al, 2016).
In contrast to the control, cells transfected with the PL1 plasmid and expressing
mEmerald-PbTLAP2-FL showed a diffuse cytosolic distribution of the fusion protein in cells
(Fig. 12-B). There were no visible green fluorescent strands resembling microtubules radiating
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throughout expressing cells, like was seen in mEmerald-TgTLAP2 expressing cells. In addition,
when looking at the merged fluorescent images of tubulin and the fusion protein, there is clearly
no overlap of the colors. Thus, there was no indication of microtubule binding. Interestingly, in
the expressing cells in green, the labeled tubulin in the same cells does not appear to be as bright
than in non-expressing cells. This could indicate that overexpression of the fusion protein
blocked tubulin antibody binding to some degree.
Considering that I generated the pC22-mEmerald-PbSaxo plasmid (PL7), along with the
pC22-mEmerald-PbTLAP2-FL plasmid (PL1), for the side investigation into whether the
PbSAXO protein might also have microtubule-binding properties, I transfected U-2 OS cells
with the PL7 plasmid. Similar to mEmerald-PbTLAP2-FL, the mEmerald-PbSAXO fusion
protein displayed a mostly diffuse cytoplasmic distribution in expressing cells (Fig. 12-C).
However, it did appear that the protein may have potentially localized to few microtubules, as
observed by the appearance of faint green fluorescent fibers that resemble microtubules in
expressing cells. Because I observed mostly diffuse distribution throughout expressing cells, I
concluded that the fusion protein did not bind to microtubules.
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Figure 12. Ectopically Expressed mEmerald-PbTLAP2-FL Displays Diffuse Cytosolic
Distribution in Cells. U-2 OS cells transfected with pC22-mEmerald-TgTlap2 (positive control)
and generated pC22-mEmerald-PbTlap2-FL expression plasmids. A) Fluorescence images of
ectopically expressed N-terminally tagged mEmerald-TgTlap2 fusion protein binding to and
bundling microtubules (middle image, yellow arrow). Yellow arrows indicate TgTLAP2 likely
blocking anti-tubulin antibody binding to microtubule epitopes as seen by lack of red tubulin
fluorescence in cells. B) Fluorescence images of expressed mEmerald-PbTLAP2-FL shows
fusion protein displaying diffuse cytosolic distribution throughout the cytosol of cells (white
arrow). C) Fluorescence images of ectopically expressed mEmerald-PbSAXO fusion protein
displays diffuse cytosolic distribution in cells with potential microtubule-binding also visible
(white arrow). mEmerald fusion proteins were labeled with primary anti-GFP (green) antibodies
and microtubules were labeled with primary anti-α-tubulin (red) antibodies. Fluorescentconjugated secondary antibodies were used in combination to the primary antibodies. DAPI
stained nuclei (blue). Far right column shows schematic representation of translated fusion
proteins. The transfection efficiency of mEmerald-TgTLAP2 was 34%, mEmerald-PbTLAP2FL 17%, and mEmerald-PbSAXO 31%. Scale bars = 20µm.
Upon further observation, I noticed that not all cells in the culture did express the fusion
proteins. Thus, in addition to analyzing the subcellular localization of mEmerald-PbTLAP2-FL
and mEmerald-PbSAXO, I calculated and compared the transfection efficiencies for PL1, PL7,
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and the control plasmid in cells. All plasmid transfections, including the control, resulted in a
rather low transfection efficiency. PL1 resulted in 17% efficiency, PL7 showed 31% efficiency,
and the control showed 34% efficiency (see Appendix F). The manufacturer of the transfection
kit indicates a typical transfection efficiency of 60-80% across a large variety of cell lines, thus
the reason for this relatively low transfection rate in U-2 OS cells is not clear. In the case of the
cytoplasmic distribution of mEmerald-PbTLAP2, I considered the possibility that the relatively
large tag (240 aa’s) combined with the large non-conserved N-terminal region of PbTLAP2,
could be somehow affecting microtubule binding function. To this end, I took a different
approach for the investigation into whether PbTLAP2 binds to microtubules. Subsequently, I
generated another plasmid to express only a C-terminal region of PbTLAP2, consisting of the
hypothetical microtubule binding domain. For a detailed list of transfection results from each
expression plasmid, refer to Appendix F.
Generation of mEmerald-PbTlap2Δ Plasmid
As another approach to determine if PbTLAP2 binds to microtubules, and to determine if
the mEmerald tag fused with the full length PbTLAP2 protein caused issues for microtubule
binding, I generated another plasmid to express only the C-terminal ~200 aa’s of the protein. I
adapted this idea from the Liu et al, 2016 paper, in which the researchers showed that the Cterminal aa’s 181-456 of TgTLAP2 are sufficient to induce microtubule binding in HeLa cells.
This approach was strengthened by the fact that the C-terminal ~200 aa’s of PbTLAP2 and
TgTLAP2 are relatively conserved (See Fig 10). Subsequently, I generated a new plasmid
coding to express only the C-terminal 347-597 aa’s of PbTLAP2 in cells, based on an alignment
with TgTLAP2 (Fig. 13).
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Figure 13. PbTLAP2 Amino Acids 347-597 Selected for Expression Study. Alignment of
PbTLAP2 and TgTLAP2 homologs showing the C-terminal PbTLAP2 region (highlighted
yellow) expressed in cells. The truncated TgTLAP2 homolog previously ectopically expressed
by other researchers is also shown (highlighted blue). PbTLAP2 and TgTLAP2 C-terminal
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regions highlighted here share 26.5% (52.3% similarity). Hypothetical microtubule-binding
domain indicated by red brackets.
To generate a plasmid to express only the aa’s 347-597 of PbTLAP2, I amplified the
corresponding sequence of pbtlap2 (nucleotide number’s 1196-1794) and used the same methods
as described for the full-length gene. The resulting plasmid is 5,455 bp in size and was named
pC22-mEmerald-PbTlap2Δ, referred to as PL2 (Fig. 14).

Figure 14. Generation of pC22-mEmerald-PbTLAP2Δ Expression Plasmid.A) Replacement of
tgtlap2 gene sequence with pbtlap2Δ gene containing a preceding Serine-Glycine-Leucine (SGL)
linker coding sequence in pC22-mEmerald-TgTlap2 plasmid template. Cloning occurred by
restriction digestion at Kpn2I and AflII restriction sites. B) Translated N-terminal tagged
mEmerald-PbTlap2Δ fusion protein. Resulting pC22-mEmerald-PbTlap2Δ plasmid (PL2) is
5,455bp in size.
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mEmerald-PbTLAP2Δ Shows Diffuse Cytosolic Distribution in Cells
To transfect PL2 plasmid into U-2 OS cells and fluorescently label microtubules as well
as the expressed fusion protein, I used the same methods as previously described (see Fig. 11).
Similar to the results of the mEmerald-PbTLAP2-FL expression findings, cells transfected with
PL2 and expressing mEmerald-PbTLAP2Δ showed a diffuse cytosolic distribution of the fusion
protein in cells (Fig. 15-B). Again, this was inconsistent with the mEmerald-TgTLAP2 control
results in which the protein showed microtubule binding. The same control fluorescent images
shown previously are included for reference (Fig. 15-A). Thus, there was no indication that
mEmerald-PbTLAP2Δ binds to microtubules in U-2 OS cells. Also like the previous
transfection of PL1, not all U-2 OS cells in culture appeared to be expressing mEmeraldPbTLAP2Δ. Thus, I calculated the transfection efficiency of PL2 and observed a calculated
efficiency of 15%.

Figure 15. Ectopically Expressed mEmerald-PbTLAP2Δ Shows Diffuse Cytosolic Distribution
in Cells. Mammalian (U-2 OS) cells transfected with pC22-mEmerald-TgTlap2 (control) and
pC22-mEmerald-PbTlap2Δ expression plasmids and expressing mEmerald-TgTLAP2 (row A)
and mEmerald-PbTLAP2Δ (row B), respectively. Fusion protein constructs are represented on
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the schemes on the right panel. Primary anti-tubulin and secondary AlexaFluor-555 antibodies
provided images in left column (red). Primary anti-GFP and secondary AlexaFluor-488
antibodies provided images in middle column (green). The right column images represent
merged image of column 1 and 2. A) mEmerald-TgTLAP2 binding to and bundling microtubules
(note same control images as shown in figure 14). B) mEmerald-PbTLAP2Δ shows diffuse
cytosolic distribution in the cytosol of transfected cells (white arrow). The transfection
efficiency of mEmeral-PbTLAP2Δ was 15%. DAPI stained nuclei (blue).
My current findings indicate that neither N-terminally tagged mEmerald-PbTLAP2-FL,
nor N-terminally tagged mEmerald-PbTLAP2Δ, bind to microtubules in U-2 OS cells. Rather,
both fusion proteins showed a diffuse cytosolic distribution when expressed in cells. The exact
reasoning behind this is not clear; however, I hypothesized that the mEmerald tag may still be
interfering with the ability of either PbTLAP2-FL or PbTLAP2Δ to bind to microtubules.
Subsequently, I generated plasmids that place the tag at the C-terminus of the protein to
investigate if the tag location could be at the root of the problem.
Generation of C-terminal GFP Plasmids
The researchers studying MAPs in T. brucei (Dacheux et al., 2012) had generated a

plasmid that expressed T. brucei SAXO (TbSAXO), a MAP6-like protein, fused with a Cterminal GFP tag. They also expressed the MAP in U-2 OS cells. Considering our lab did not
currently have an expression plasmid to tag a protein with C-terminal GFP tag, I made an inquiry
to the authors of the TbSAXO paper about receiving this plasmid as a template for my research.
Subsequently, I was kindly gifted the expression plasmid pcDNA3.1-TbSaxo-Myc/stop-GFP
(Fig. 16) from Dr. Bonhivers, Bordeaux University, France. Notably, this plasmid template, in
addition to the GFP tag, also contained a Myc reporter tag, which allows for expressing a gene of
interest with either a GFP or a Myc tag. The expression of the gene of interest is driven by a
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CMV promoter. Thus, I was able to use this new plasmid as a template to generate C-terminal
GFP expression plasmids for PbTLAP2-FL and PbTLAP2Δ.

Figure 16. Plasmid MAP of pcDNA3.1-TbSaxo-myc/stop-GFP. Expression plasmid map
showing all components of pcDNA3.1-TbSaxo-Myc/stop-GFP. It contains a CMV promoter
driving expression of either TbSAXO-Myc or TbSAXO-GFP fusion proteins dependent on
presence of stop codon following the Myc tag, if present. It also contains an ampicillin resistance
gene (AmpR). Plasmid figure created using SnapGene.
To generate the C-terminal GFP expression plasmids, I replaced the tbsaxo gene with
either the pbtlap2-FL or pbtlap2 sequence. The forward primers to PCR amplify either pbtlap2FL or pbtlap2 were designed with a KpnI enzyme restriction site and reverse primers were
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designed with the XbaI enzyme site (Table 1, P17 & P19) (Table 1, P18). The tbsaxo gene was
removed from the template using the KpnI and XbaI enzymes. Subsequently, the pbtlap2 PCR
amplified fragments were purified and then ligated into the digested template (Fig 17-A, C). The
resulting generated plasmids were named pcDNA3.1-PbTlap2-FL-GFP (PL3) and pcDNA3.1PbTlap2-GFP (PL4). In addition, I generated Myc-tag plasmids for PbTLAP2, which I will
elaborate on later. In addition to PL3 and PL4 plasmids, I generated a plasmid to express
PbSAXO-GFP using the same methods as previously described (Fig. 17-E). The resulting
plasmid was named pcDNA3.1-PbSaxo-GFP (PL9). I also edited the pcDNA3.1-TbSaxoMyc/stop-GFP plasmid template by removing the Myc/stop sequence so that I could express
TbSAXO-GFP as an additional control (Fig. 17-G). Generating this plasmid was necessary
because the unaltered plasmid template produces translated TbSAXO with a Myc tag only. To
construct the plasmid, the Myc/stop sequence was removed from the template by digesting the
plasmid at the XbaI restriction sites. Following digestion, the plasmid was re-circularized
resulting in a 6,926 bp plasmid. I named the plasmid pcDNA3.1-TbSaxo-GFP.
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Figure 17. Generation of C-terminal GFP-tagged Expression Plasmids: 1) pcDNA3.1-PbTlap2FL-GFP, 2) pcDNA3.1-PbTLAP2Δ-GFP, 3) pcDNA3.1-PbSaxo-GFP, and 4) pcDNA3.1TbSaxo-GFP. A) Insertion of pltlap2-FL gene into pcDNA3.1-TbSaxo-Myc/stop-GFP plasmid
template at KpnI and XbaI restriction sites. B) Translated PbTLAP2-FL-GFP fusion protein. C)
Insertion of pbtlap2Δ into pcDNA3.1-TbSaxo-Myc/stop-GFP plasmid template at KpnI and XbaI
restriction sites. D) Translated PbTLAP2Δ-GFP fusion protein. E) Insertion of pbsaxo gene into
pcDNA3.1-TbSaxo-Myc/stop-GFP plasmid template at KpnI and XbaI restriction sites. F)
Translated PbSAXP-GFP fusion protein G) Performed plasmid cloning to remove myc/stop tag
sequence from pcDNA3.1-TbSaxo-Myc/stop-GFP control plasmid. H) Translated TbSAXO-GFP
fusion protein control.
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PbTLAP2Δ-GFP Shows Diffuse Cytosolic Distribution in Cells
To transfect the C-terminal GFP plasmids into U-2 OS cells and fluorescently label
microtubules as well as the expressed fusion protein, I used the same methods as previously
described (see Fig. 11). U-2 OS cells transfected with the pcDNA3.1-TbSaxo-GFP control and
expressing TbSAXO-GFP showed a diffuse cytoplasmic distribution of the fusion protein
throughout the cells (Fig. 18-A). I did not observe a fluorescent green network, resembling
microtubules, running throughout expressing cells. The merged image clearly showed no
overlap between labeled tubulin and fusion protein. Thus, I concluded that TbSAXO-GFP fusion
protein does not bind to microtubules. This was surprising as I was expecting to observe
microtubule binding by TbSAXO-GFP, considering Dacheux et al, 2012 showed that TbSAXO
tagged with Myc binds to microtubules in U-2 OS cells.
Because I had generated the pcDNA3.1-PbSaxo-GFP (PL8) plasmid, I also transfected
this into U-2 OS cells. Following transfection with PL8 and IF, it appeared that cells were
highly stressed, indicated by decreased cell size and a less extensive array of cytoplasmic
microtubules (Fig. 18-B). Although I did notice few cells that were expressing PbSAXO-GFP, it
is unclear whether the fusion protein binds to microtubules in cells due to the stress. It is
possible that the fusion protein may have some potential for microtubule binding, similar to
mEmerald-PbSAXO (see Fig. 12-C), however repeat experiments are necessary for further
investigation.
Surprisingly, in cells transfected with PL3 plasmid, I did not observe any successful
expression of PbTLAP2-FL-GFP fusion proteins. There were no cells showing even a green
diffuse fluorescence like I observed with other transfections. Rather, I observed a punctate green
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fluorescence seemingly outside some of the U-2 OS cells (Fig. 18-C). Thus, this green
fluorescence was likely an artifact. I also noted that the cells transfected with PL3 appeared to
be stressed, showing similar indications observed following the previous transfection with PL8.
Due to these issues, repeat transfections with this plasmid would be necessary to see if better
results can be obtained and whether the fusion protein binds to microtubules or not.
Similar to the TbSAXO-GFP control experiment, transfection of PL4 plasmid and
expression of PbTLAP2-GFP in cells resulted in a diffuse distribution of the fusion protein
throughout the cytosol (Fig. 18-D). Like to control, I did not observe any sort of radiating
network resembling microtubules in expressing cells. There was also no obvious co-localization
of the fusion protein to microtubules because the merged image clearly showed no overlap
between labeled tubulin and the fusion protein.
Similar to previous transfections, I noted that only a small fraction of the cells was
expressing C-terminal GFP fusion proteins . Thus, I again calculated the efficiencies of each of
the transfections and the results were as follows: pcDNA3.1-TbSaxo-GFP resulted in 23%
efficiency, PL8 plasmid resulted in 38% efficiency, and PL4 plasmid resulted in 19% efficiency.
Note I did not calculate efficiency of PL3 transfection due to highly stressed cells and poor
results. Similar to previous transfections with the mEmerald tag plasmids, the GFP tag plasmids
resulted in low transfection efficiencies (see appendix F). The exact reasoning for the low
transfection efficiencies in not clear.
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Figure 18. Ectopically Expressed PbTLAP2Δ-GFP and PbSAXO-GFP Show Diffuse Cytosolic
Distribution in Cells. Mammalian (U-2 OS) cells transfected with pcDNA3.1-TbSaxo-GFP
(control), pcDNA3.1-PbSaxo-GFP, pcDNA3.1-PbTlap2-FL-GFP, and pcDNA3.1-PbTlap2ΔGFP expression plasmids and expressing TbSAXO-GFP (row A), PbSAXO-GFP (row B),
PbTLAP2-FL-GFP (row C), and PbTLAP2Δ-GFP (row D). Fusion protein constructs are
represented on the schemes on the right panel. Primary anti-tubulin and secondary AlexaFluor555 antibodies provided images in left column (red). Primary anti-GFP and secondary
AlexaFluor-488 antibodies provided images in middle column (green). The right column images
represent merged image of column 1 and 2. A) Fluorescence images showing diffuse cytosolic
distribution of TbSAXO-GFP in U-2 OS cells. B) Fluorescence imaging of ectopic expression of
C-terminal tagged PbSAXO-GFP displaying diffuse cytosolic distribution throughout the cytosol
of cells as well as cells that are likely highly stressed. C) No expression of PbTLAP2-FL-GFP in
cells and unknown punctate fluorescence surrounding cells. D) PbTLAP2Δ-GFP shows diffuse
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cytosolic distribution in cells. The transfection efficiency of TbSAXO-GFP was 23%, PbSAXOGFP was 38%, and PbTLAP2Δ-GFP was 19%. DAPI stained nucleio (blue).
Taking into consideration the previous findings and the results using the C-terminal GFP
tag, I hypothesized that the large 240 aa GFP tag, whether located at the N- or C-terminus of
PbTLAP2, could be interfering with the protein’s ability to bind to microtubules. After all, the
GFP tag is 95% of the size of PbTLAP2 and 40% of the size of PbTLAP2-FL. Subsequently, I
considered yet another approach to tagging PbTLAP2 to rule out the possibility of GFP causing
issues. Upon further review of the Dacheux et al, 2012 paper, I found that the authors presented
their findings of TbSAXO co-localized to microtubules in U-2 OS cells when expressing
TbSAXO fused with a C-terminal Myc reporter tag. Thus, I considered expressing PbTLAP2
with a C-terminal Myc tag in U-2 OS cells. This was also a convenient approach, because as
mentioned earlier, the control plasmid template we received contained a tag for GFP or Myc.
Thus, I performed some additional cloning to generate Myc tag plasmids.
Generation of Myc Tag Plasmids
The Myc tag is commonly used in gene expression studies and is derived from the c-myc
proto-oncogene that is important for cellular proliferation (Chi V. Dang, 1999). Notably, the
Myc-tag is comprised of only 10 aa’s while the mEmerald/GFP protein tags are about 24 times
larger. To generate the expression plasmids for PbTLAP2-FL-Myc and PbTLAP2-Myc, I used
the already generated PL3 and PL4 plasmids as templates (Fig. 19-A, C). To clone the Myc
sequence, including a stop codon, into PL3 and PL4 plasmids, I used the previously generated
Myc/stop fragment (174bp) that was digested and purified from pcDNA3.1-TbSAXO-Myc/stopGFP, and subsequently cloned the fragment into PL3 and PL4 at the XbaI restriction enzyme
sites. The resulting plasmids were named pcDNA3.1-PbTLAP2-FL-Myc (PL5) and pcDNA3.1-
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PbTlap2-Myc (PL6). In addition to the PL5 and PL6 plasmids, I generated a plasmid (Fig. 19E) for expression of PbSAXO-Myc in cells. To generate the plasmid, I used the same methods
used previously to generate PL5 and PL6 plasmids, however using the pcDNA3.1-PbSaxo-GFP
(PL8) as the plasmid template. The resulting plasmid was named pcDNA3.1-PbSaxo-Myc
(PL9).

Figure 19. Generation of C-terminal Myc-tagged Expression Plasmids: pcDNA3.1-PbTlap2-FLMyc and pcDNA3.1-PbTlap2Δ -Myc. A) Insertion of Myc/stop sequence into pcDNA3.1PbTlap2-FL-GFP plasmid template at XbaI restriction site. B) Translated PbTLAP2-FL-Myc
fusion protein. C) Insertion of Myc/stop sequence into pcDNA3.1-PbTlap2Δ -GFP plasmid
template at XbaI restriction site. D) Translated PbTlap2Δ-Myc fusion protein. E) Insertion of
Myc/stop sequence into pcDNA3.1-PbSaxo-GFP plasmid template at XbaI restriction site. F)
Translated PbSAXO-Myc fusion protein.
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PbTLAP2-Myc and PbSAXO-Myc Bind to Microtubules in Cells
To transfect the C-terminal Myc tag plasmids into U-2 OS cells and fluorescently label
microtubules as well as the expressed fusion protein, I used the same methods as previously
described (see Fig. 11). However, the specific antibodies used for labeling the Myc fusion
protein were different due to the change in protein tag. Thus, I used primary anti-Myc and
secondary AlexaFluor-488 antibodies to label the fusion proteins. The same antibodies used
previously to label microtubules were used.
U-2 OS cells transfected with the pcDNA3.1-TbSaxo-Myc control plasmid and
expressing TbSAXO-Myc showed clear binding of the fusion protein to microtubules (Fig. 20A). I could clearly observe a green fluorescent radiating network of strands, resembling
microtubules, in most cells. Successful microtubule co-localization was confirmed in the merged
image of tubulin and the expressed fusion protein in which a yellow fluorescence overlay
resulted. Also, I could clearly see a higher concentration of the fusion protein localized around
the nucleus of each cell, which makes sense considering the MTOC is located there.
Interestingly, the cytoplasmic microtubules were clearly spanning the outside of the nucleus,
resulting in a highly visible nucleus in each U-2 OS cell. These findings were consistent with the
results of the Dacheux et al., 2016 paper that showed TbSAXO-Myc binding to microtubules.
In line with the findings of the TbSAXO-Myc expression results, I observed clear binding
of PbSAXO-Myc in cells transfected with the PL9 plasmid (Fig. 20-B). Just like in the control
transfection, I observed a nice array of green fluorescent strands extending throughout
expressing cells that resembled microtubules. Also similar to the control, the merged image of
cytoplasmic microtubules and PbSAXO-Myc resulted in a yellow fluorescent overlap, indicating
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co-localization of the fusion protein and microtubules. I noticed that the green fluorescence of
the localization of the fusion protein to microtubules seemed to be more pronounced than in the
control. It almost appeared that PbSAXO-Myc may have had a better binding affinity than
TbSAXO-Myc. Finally, it also appeared that there was a higher concentration of fusion protein
localized to the MTOC than in the control transfection, based on brighter green fluorescence in
this region.
Following transfection of PL5 and expression of PbTLAP2-FL-Myc, the fusion protein
also showed binding to microtubules in U-2 OS cells, similar to TbSAXO-Myc and PbSAXOMyc (Fig. 20-C). However, compared to PbSAXO-Myc, the localization of PbTLAP2-FL-Myc
did not appear as pronounced, based on faint green fluorescence along the microtubule network.
U-2 OS transfected with PL6 plasmid and expressing PbTLAP2-Myc resulted in
binding of the fusion protein to microtubules, similar to what I observed for all previous Myc tag
plasmid transfections (Fig. 20-D). The binding affinity of PbTLAP2-Myc appeared to be
higher than PbTLAP2-FL-Myc, similar to that of PbSAXO-Myc. This was again based on a
more defined and visible network of green fluorescent strands that radiated throughout cells and
resembled the cytoplasmic microtubules. The microtubule binding was confirmed when the
green fluorescence was localized along the microtubules in the merged image. Note I included
confocal imaging for expression of this fusion protein from two different imaging sessions. I
obtained good images from both session showing microtubule co-localization, so I decided to
include both in the figure for added confirmation.
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Figure 20. Ectopically Expressed PbTLAP2-FL-Myc, PbTLAP2Δ-Myc, and PbSAXO-Myc
Binds to Microtubules. Mammalian (U-2 OS) cells transfected with pcDNA3.1-TbSaxo-Myc
(control), pcDNA3.1-PbSaxo-Myc, pcDNA3.1-PbTLAP2-FL-Myc, or pcDNA3.1-PbTLAP2ΔMyc expression plasmids and expressing TbSAXO-Myc (row A), PbSAXO-Myc (row B),
PbTLAP2-FL-Myc (row C), and PbTLAP2Δ-Myc (row D). Fusion protein constructs are
represented on the schemes on the right panel. Primary anti-tubulin and secondary AlexaFluor-
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555 antibodies provided images in left column (red) Primary anti-Myc and secondary
AlexaFluor-488 antibodies provided images in middle column (green). A-D)TbSAXO-Myc,
PbSAXO-Myc, PbTLAP2-FL-Myc, and PbTLAP2Δ-Myc bind to microtubules in cells (white
arrows). Bottom row in box D is separate set of images for PbTLAP2Δ-Myc also displaying
binding to microtubules in cells. The efficiency of all plasmid transfections was >90% in cells.
DAPI stained nuclei (blue).
Compared to the previous transfections with PL1-PL4 plasmids and expression of
mEmerald and GFP tagged PbTLAP2, I immediately noticed a much higher percentage of cells
showing successful expression of Myc tagged PbTLAP2. Thus, to get a better idea for the
difference in efficiency, I calculated the transfection efficiency for the control, PL5, PL6, and
PL9 Myc plasmids. Based on my observations and calculations, the transfection efficiencies of
all Myc plasmids were higher than 90%, including the control. Although this did seem to be a
rather high transfection efficiency, the manufacturer of the transfection kit does claim that a high
rate of transfection efficiency should be achieved.
These data show for the first time that PbTLAP2, as well as PbSAXO, bind to
microtubules in U-2 OS cells, thereby identifying the novel proteins as MAPs. These findings
also show that the C-terminal 347-597 aa’s of PbTLAP2 are sufficient for microtubule binding.
Subsequently, due to the high conservation between human and Plasmodium tubulin and the fact
that I have shown that PbTLAP2 binds to microtubules in U-2 OS cells, I hypothesize that
PbTLAP2 should also bind to microtubules in the Plasmodium parasite.
Investigation of PbTLAP2 Microtubule Stabilization Against Cold
Considering that Dacheux et al, 2012 showed that expressed TbSAXO-Myc stabilizes
microtubules against cold (4°C) in U-2 OS cells, I next investigated whether PbTLAP2 has the
same effect on microtubules. To this end, I used the Myc-tag plasmids for stabilization
experiments because expressed protein with the Myc tag were the only fusion proteins that
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showed microtubule binding in U-2 OS cells. I used U-2 OS cells for microtubule stabilization
experiments because microtubules in these cells readily destabilize at 4°C (Delphin et al., 2012).
In many other eukaryotic cell types, microtubules remain cold-stabile due to associations with
stabilizing proteins, such as the major microtubule-stabilizing family of MAP6s. However, U-2
OS cells lack expression of MAP6, thereby rendering the microtubules susceptible to cold
destabilization (Delphin et al., 2012).
First, I verified that I could perform cold treatment of the U-2 OS cells I had available
before moving forward with plasmids transfections. To induce microtubule destabilization, a
confluent culture of U-2 OS cells was cold-treated by replacing the culture media with prechilled (4°C) complete medium and subsequently incubating the cells at 4°C for 30 minutes.
Cells were then immediately fixed, and IF was carried out as previously described (see methods
and Fig. 13).
Confocal microscopy revealed that the non-cold treatment cells, kept constantly at 37°C
in culture, looked as expected with a normal distribution of microtubules in U-2 OS cells (Fig.
21-A). However, the cold-treated cells appeared to be smaller and thus the microtubules, while
discernable, failed to extend as far from the MTOC compared to the non-treatment cells. (Fig.
21-B). It also appeared that microtubules are less defined in the cold-treated cells, as one would
expect as a result of depolymerization. In addition, I observed brighter red fluorescence
surrounding the nucleus of treated cells at the likely MTOC, indicating that tubulin may have
accumulated their following microtubule depolymerization. Importantly, the nuclei in treated
cells appeared to remain in proper shape and size, consistent with the non-treated cells. This
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supports my finding that the microtubules destabilized in cells and not that the cells were just
stressed and reduced in size and morphology.

Figure 21. Microtubule Destabilization in Cold treated U-2 OS Cells. Microtubules in U-2 OS
cells destabilized following cold treatment. Microtubules were labeled with anti-αtubulin fluorescently conjugated antibodies (red). Cell measurement (µm) measured in cold and
non-treated cells (white bars). Location of microtubule organization center (white arrows) more
visible in cold treatment cells (right). Nuclei (N) stained with DAPI.
To get a better idea of the degree of microtubule destabilization that occurred in treated
cells, I calculated the approximate percent difference in length of microtubules in treated vs. nontreated cells (Table 8). The cell length of five treated and five non-treated cells located in a
130uM FOV were measured in micrometers. The average cell length from each group was then
calculated and recorded. Based on my observations and calculations, there was a 74% decrease
in the average length of cells in the cold treatment, compared to the control non-treated cells.
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Table 6. Cell Length in Cold-treated vs. non-Cold treatment U-2 OS cells. The cell length (µm)
of five U-2 OS cells treated at 4°C for 30 minutes was measured. In addition, the cell length of
five non cold-treated cells was measured. The average cell length was calculated for each group
(treatment and non-treatment) and the % decrease in length between each group was calculated.
PbTLAP2 Shows Potential Microtubule Stabilization Against Cold in Cells
For stabilization experiments, I used the same transfection and IF methods as previously
used to fluorescently label microtubules and expressed fusion proteins in cells. First, U-2 OS
cells in culture were transfected with either the pcDNA3.1-TbSaxo-Myc control, PL5, PL6, or
PL9 plasmids. Following transfection, cells were then cold treated as described, fixed in PFA,
and finally IF was carried out for fluorescent labeling.
In comparison to previously non-treated (37°C) U-2 OS cells that were transfected with
the pcDNA3.1-TbSAXO-Myc plasmid, cold-treated (4°C) cells transfected with this control and
expressing TbSAXO-Myc resulted in the appearance of stabilized cytoplasmic microtubules
(Fig. 22-A). Note that I duplicated the images from previous transfections under normal
conditions (37°C) and used them in figure 22 for comparison against the cold treatment cells.
The stabilized cytoplasmic microtubules looked similar to the normal structure of microtubules
as seen in the non-treatment control; however, the microtubules in the cold treated cells seemed
more visible and abundant than in the non-treatment. This could suggest that the expressed
TbSAXO-Myc was heavily recruited to the microtubules as soon as the temperature decreased
and thus kept the microtubules intact. The image with expressed and fluorescent green labeled

71
TbSAXO-Myc showed the vast network of stabilized microtubule strands extending from around
the nucleus to the periphery of the cells. Also, the nucleus appeared to fluoresce brighter in the
expressing cold-treated cells compared to the non-treatment. Thus, it is possible that the fusion
protein localization was higher around the nucleus, perhaps near the MTOC, however this would
need to be investigated further to confirm. There also appeared to be a series of small, bright
fluorescent dots on the nucleus as well in the cold treatment cells expressing the fusion protein.
Interestingly, I observed this phenomenon several times throughout independent experiments and
this was not previously reported elsewhere. Our lab may further investigate this in the near
future. These findings suggest that the presence of TbSAXO-Myc in the cold treatment cells
resulted in the fusion protein protecting the microtubules against depolymerization. Stabilization
was also confirmed based on the fact that the length of the cells expressing the fusion protein did
not appear to be reduced. Also, in the cells that were not expressing the fusion protein, the cell
length appeared reduced, which was likely a result of microtubule destabilization. This
observation was consistent with the cold treatment findings of the non-transfected cells (see Fig.
22-B). The cells that were expressing TbSAXO-Myc were roughly 80µm in length, which is
slightly longer than those in the non-treatment control (see Fig. 22-A). My findings are
consistent with findings by Dacheux et al, 2012, who also showed that TbSAXO had microtubule
cold-stabilization properties.
As I had previously looked into potential microtubule binding by PbSAXO, I also
decided to investigate whether this protein would stabilize microtubules. So, as a side project I
looked into PbSAXO stabilization along with PbTLAP2. Including PbSAXO was in these
experiments was also important because it is a homologous protein to the control I am using,
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TbSAXO. Therefore, I could use my PbSAXO findings, in addition to the control, to inform the
findings of the PbTLAP2 stabilization investigation. Thus, I transfected U-2 OS cells with PL9
plasmid to express PbSAXO-Myc and then cold-treated (4°C) the cells. Consistent with how I
am presenting my TbSAXO-Myc control results, I am including images from previous
transfections with PL9 plasmid under normal conditions (37°C). Following cold treatment, I
observed microtubules extending across the length of an expressing cell, suggesting that the
fusion protein may have stabilized the microtubules against cold (Fig. 22-B). The merged image
of tubulin and expressed PbSAXO-Myc indicated that the protein did in fact bind to
microtubules in treated cells. The microtubules in treated cells expressing the fusion protein, as
well as not expressing, appear to have destabilized. The destabilization appears to be more
significant in the non-expressing cells, however. This is consistent with cold treated cells that
were non-transfected with plasmids, as well as cold treated cells that were expressing the
TbSAXO-Myc control. However, the expressing cell length was roughly 60µm in length, which
is slightly less than those in the non-treatment control (see Fig. 22-A). As implied, the
potentially stabilized microtubules in the cell expressing PbSAXO-Myc appear to messy and not
nearly as stabilized as those stabilized when expressing TbSAXO-Myc. In addition, the cells
transfected with PL9 plasmid appear to be rather stressed, as indicated by reduced size and
morphology. It is important to note that I included cold treatment images for this plasmid
transfection that were captured using the Olympus confocal microscope, which is why the nuclei
are not stained blue. In conclusion, although I am suggesting that PbSAXO-Myc may
potentially stabilize microtubules at 4°C, repeat experiments are required to confirm or deny this.
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In comparison to previously non-treated (37°C) U-2 OS cells that were transfected with
PL5 plasmid, cold-treated (4°C) cells transfected with this plasmid and expressing PbTLAP2Myc resulted in no indication of stabilized cytoplasmic microtubules (Fig. 22-C). I observed a
punctate green fluorescent pattern along what appears to be the periphery of cells following cold
treatment, leading me to believe that there may have been problems associated with this
experiment. Perhaps the cells did not properly express the PbTLAP2-FL-Myc fusion protein.
However, consistent with the non-transfected and cold treatment control (see Fig. 22-B), it
looked as though the cell length did shrink in the cells transfected with PL5 and cold treated.
This suggests that PbTLAP2-FL-Myc was either not properly expressed in cells, or that it had no
effect on stabilizing microtubules at 4°C. Due to the strange findings when transfecting PL5 in
cells followed by cold treatment, it is necessary to repeat this experiment to attempt to get better
results.
In U-2 OS cells transfected with PL6 plasmid and expressing PbTLAP2Δ-Myc, followed
by 4°C cold treatment, I observed what appeared to be stabilized cytoplasmic microtubules (Fig.
22-D). Consistent with the non-transfected and col treatment control (see Fig. 22-B),
cytoplasmic microtubules were depolymerized in cells not expressing PbTLAP2Δ-Myc;
however, it appeared that these microtubules were completely absent. In contrast, the
microtubules in the cold treatment, non-transfected control were highly visible, but were just
reduced in length. The exact reasoning behind this is not known. Also, although I observed
what appears to be stabilized microtubules by association with PbTLAP2Δ-Myc, the
microtubules are not as organized and abundant as those in the TbSAXO-Myc control treatment
(see Fig. 22-A). The cell that was expressing PbTLAP2Δ-Myc was roughly 80µm in length,
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which is slightly longer than those in the non-treatment control (see Fig. 22-A), which supports
the findings that the microtubules were stabilized. Also, unlike the TbSAXO-Myc control, I did
not observe a brighter fluorescing nucleus or the small, bright fluorescent dots on the nucleus in
PbTLAP2Δ-Myc expressing and cold-treated cells. The microtubule stabilization by
PbTLAP2Δ-Myc was further supported by merging tubulin and anti-Myc fluorescent images,
which showed that the green fluorescent fusion protein aligned with the red fluorescent tubulin
staining. Taken together, these findings suggest that the presence of PbTLAP2Δ-Myc in the cold
treatment cells resulted in the fusion protein potentially protecting the microtubules against
depolymerization. This would also indicate that the C-terminal 253 aa’s of PbTLAP2 is
sufficient to stabilize microtubules. However, further experiments would be recommended to
confirm this finding.
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Figure 22. Ectopically Expressed PbTLAP2Δ-Myc Stabilizes Microtubules at 4°C. Transfection
of U-2 OS cells with either pcDNA3.1-TbSaxo-Myc, pcDNA3.1-PbSaxo-Myc, pcDNA3.1-
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PbTLAP2-FL-Myc, or pcDNA3.1-PbTLAP2Δ-Myc Plasmids and cold treated (4°C for 30 min)
to test for microtubule stability. Microtubules labeled with anti-tubulin (red) antibodies and
expressed fusion proteins labeled with anti-Myc (green) antibodies. Far right column is merged
images. A) Untreated (37°C) and cold-treated (4°C) cells expressing TbSAXO-Myc. TbSAXOMyc cold stabilizes microtubules in cells (white arrow) and shows potential localization to
nuclear envelope (yellow arrow). Low expression of fusion protein shown (purple arrow). B)
Untreated and cold-treated cells expressing PbSAXO-Myc. PbSAXO-Myc shows potential
microtubule stabilization against cold in cells (white arrow). C) Untreated and cold-treated cells
expressing PbTLAP2-FL-Myc. PbTLAP2-FL-Myc failed to show expression in cells as there is
no presence of fluorescently-labeled microtubules in cells. C) Untreated and cold-treated cells
expressing PbTLAP2Δ-Myc. PbTLAP2Δ-Myc cold shows potential microtubule stabilization
against cold in cells (white arrow). Scale bars: 20 µm.
Investigation of PbTLAP2 Microtubule Stabilization Against Nocodazole
To further investigate the microtubule stabilization properties of PbTLAP2, I next tested
whether the protein would stabilize microtubules against a known chemical agent that
destabilizes microtubules, called nocodazole. Nocodazole, also known as oncodazole, is
routinely used in microtubule research and is also used as a chemotherapeutic drug as it
interrupts the microtubule cytoskeleton of cancer cells, thereby preventing cell proliferation. The
drug does not cause microtubule structures themselves to depolymerize, but rather is binds to
free tubulin subunits in cells and thereby preventing them from polymerizing microtubules.
Thus, nocodazole will cause entire cell microtubule destabilization as the microtubule structures
naturally depolymerize during dynamic instability and cannot polymerize again in the presence
of the drug (Hoebeke et al., 1976).
Similar to microtubule stabilization against cold, Dacheux et al. found that TbSAXO
protects microtubules against destabilization in the presence of nocodazole. Thus, I
hypothesized that PbTLAP2 also stabilize microtubules against nocodazole. Using our
established U-2 OS cell system, I first tested the efficiency of nocodazole on U-2 OS cells before
proceeding to plasmid transfections into cells. Nocodazole was added to complete medium at a
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concentration of 20µM and incubated for 30 minutes at 37°C. Following treatment, cells were
immediately fixed in PFA and the microtubules were labeled with anti-tubulin antibodies and
observed under the confocal microscope.
Non-treated U-2 OS cells showed a normal array of microtubules extending to the
perimeter of cells (Fig. 23-A). In one cell, the location of the MTOC appears to be visible. In
stark contrast, U-2 OS cells treated with nocodazole showed significant destabilization of
microtubules as evident by a complete absence of microtubule structures throughout all cells
(Fig. 23-B). Rather, it appeared that the complete microtubule depolymerization resulted in a
localization of individual tubulin heterodimers throughout the cytosol of cells. Interestingly, in
some of the treated cells, the nuclei shape appeared to be disrupted as well, as indicated by a
dotted pattern of staining.

Figure 23. Microtubule Destabilization in Nocodazole Treated U-2 OS Cells. A) Fluorescently
labeled microtubules (red) remain stabilized with normal distribution in untreated U-2 OS cells
(red). B) Fluorescently labeled microtubules in U-2 OS cells destabilize following treatment in
20µm nocodazole for 30 minutes. Microtubules labeled with anti-α-tubulin fluorescently
conjugated antibodies. Microtubule organizing center (MTOC) labeled in non-treatment image.
MTOC non-visible in treated cells. Nuclei (N) stained with DAPI.
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PbTLAP2 Does Not Protect Microtubules Against Nocodazole-induced Destabilization
Having shown that I could depolymerize U-2 OS cell microtubules using nocodazole, I
next began transfecting U-2 OS cells with the Myc tag plasmids as I previously did in the cold
treatment study. Following plasmid transfection, I then treated the cells with 20µM nocodazole
for 30 minutes at 37°C. Following treatment, the cells were fixed in PFA and then microtubules
and Myc fusion proteins were labeled and confocal microscope images were captured following
the same protocol as previously used.
In U-2 OS cells transfected with pcDNA3.1-TbSaxo-Myc and expressing TbSAXO-Myc,
followed by nocodazole treatment, I did not observe stabilized cytoplasmic microtubules (Fig.
24-A). In the tubulin stain image, I can clearly see that the majority of microtubules were almost
completely depolymerized, with the exception of some remaining microtubules surrounding the
nucleus of one cell. The TbSAXO-Myc expression and nocodazole treatment results appear
more like the non-transfected and nocodazole treated control, in which there is complete
destabilization of cytoplasmic microtubules. Similar to what I observed and described in coldtreated cells that were expressing TbSAXO-Myc, the nuclei in the nocodazole-treated cells
showed brighter green fluorescence in cells expressing TbSAXO-Myc. It is unclear whether this
is caused by a higher concentration of the fusion protein around the nucleus, or if something else
is causing the brighter fluorescence. I clearly noticed that not all cells appeared to be expressing
the fusion protein in the nocodazole treatment, based on the absence of green fluorescence in
many cells. I also observed different expression levels in the expressing cells. Some clearly
showed brighter green fluorescence, while others had low fluorescence. This is interesting
considering that in the non-treatment, most all cells appeared to be equally expressing the fusion
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protein. Taking these findings into consideration, it appears that TbSAXO does not stabilize
microtubules against nocodazole; however, future experiments would be necessary to confirm or
deny this.
Similar to the results of the transfection with pcDNA3.1-TbSaxo-Myc and nocodazole
treatment, U-2 OS cells transfected with PL9 and expressing PbSAXO-Myc showed that the
fusion protein likely did not stabilize microtubules against nocodazole (Fig. 24-B). Consistent
with the non-transfected and nocodazole treatment results (see Fig 24-B), the tubulin stain in the
PL9 transfected and nocodazole treatment showed a complete destabilization of the
microtubules. Also, in the PbSAXO-Myc stain, I did not observe any discernable microtubule
structures in the expressing cells.
Also similar to the results of the transfection with pcDNA3.1-TbSaxo-Myc and
nocodazole treatment, U-2 OS cells transfected with PL5 and expressing PbTLAP2-FL-Myc
showed that the fusion protein likely did not stabilize microtubules against nocodazole (Fig. 24C). Also consistent with the non-transfected and nocodazole treatment results (see Fig 24-B), the
tubulin stain in the PL5 transfected and nocodazole treatment showed a complete destabilization
of the microtubules. Finally, in the PbTLAP2-FL-Myc stain, I did not observe any discernable
microtubule structures in the expressing cells. I observed the same results when transfecting
with PL6 and expressing PbTLAP2-Myc in U-2 OS cells as was observed for the transfection
and treatment with PL5 plasmid (Fig. 24-D). Taking these findings into consideration, I
concluded that neither PbTLAP2-FL-Myc or PbTLAP2-Myc stabilized microtubules against
nocodazole. Again, I think more investigation into this is needed. Thus, our lab plans to
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continue to look into PbTLAP2 stabilization against nocodazole, and perhaps other microtubuledestabilizing drugs, in the near future.
Based on the fact that I observed differing transfection levels in some of the transfections
with nocodazole treatment, I again quantified the transfection efficiencies for each plasmid. The
results of my observations and calculations are as follows: transfection with pcDNA3.1TbSAXO-Myc was 43% and the efficiency of PL5, PL6, and PL9 plasmids were all >90%. The
high transfection efficiencies with PL5, PL6, and PL9 was consistent with my findings when
transfecting these plasmids and employing no treatment as well as with the cold treatment.
Interestingly, the lower transfection efficiency of pcDNA3.1-TbSAXO-Myc was similar to what
I observed in the cold treatment.
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Figure 24. Ectopically Expressed PbTLAP2-FL-Myc and PbTLAP2Δ-Myc Fail to Stabilize
Microtubules Against Nocodazole. Transfection of U-2 OS Cells with either pcDNA3.1-TbSaxo-
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Myc, pcDNA3.1-PbTLAP2-FL-Myc, or pcDNA3.1-PbTLAP2Δ-Myc plasmids and treatment
with 20µM nocodazole to test for microtubule stability. Microtubules fluorescently labeled with
primary anti-tubulin (red) and expressed fusion protein fluorescently labeled with primary antiMyc (green) antibodies. AlexaFluor-488 and AlexaFluor-555 secondary antibodies used with
primary antibodies. A) Fluorescence images of untreated and nocodazole treated cells expressing
TbSAXO-Myc. TbSAXO-Myc does not appear to stabilize microtubules against nocodazole in
cells. Rather, shows potential localization to nuclear envelope. B) Untreated and nocodazole
treated cells expressing PbSAXO-Myc. PbSAXO-Myc shows potential microtubule stabilization
against nocodazole in cells. C) Untreated and nocodazole treated cells expressing PbTLAP2-FLMyc. PbTLAP2-FL-Myc shows potential microtubule stabilization against nocodazole in cells.
D) Untreated and nocodazole treated cells expressing PbTLAP2Δ-Myc. PbTLAP2Δ-Myc shows
potential microtubule stabilization against nocodazole in cells. DAPI stained nuclei (blue). Scale
bars: 20 µm.
CRISPR/Cas9-Mediated Gene Deletion
The CRISPR/Cas9 gene-editing system is a method for efficient and effective editing,
deletion, or modification of any gene in any organism. It is derived from a naturally occurring
defense mechanism consisting of Clustered Regularly Interspaced Short Palindromic Repeats
(CRISPR) occurring in bacteria to recognize and protect against invading bacteriophages.
Kaitlyn Kiernan, a former graduate student in the lab, adapted the CRISPR system to P. berghei
and successfully deleted two genes (Kiernan et al., in prep). My goal was to use Kaitlyn’s
plasmid as a template to generate a CRISPR/Cas9 deletion plasmid targeting the pbtlap2 gene in
the parasite. The deletion plasmid would be used to generate a P. berghei tlap2 knockout
(pbtlap2-KO) line and to study any potential phenotype. My hypothesis was that P. berghei KO
parasites, lacking expression of the PbTLAP2 protein, will develop a malformed structure.
Because I have shown previously that PbTLAP2 binds to and likely stabilizes microtubules in U2 OS cells, in KO parasites, I would expect to see destabilization of cytoskeletal microtubules
which may result in severely misshapen parasite structure.
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Homology-Directed Repair to Enable Gene Deletion
The CRISPR/Cas9 system that I am using utilizes homology-directed repair (HDR) to
replace the endogenous gene with a disruptor (Dis) sequence that ultimately facilitates the
deletion of the pbtlap2 gene. The molecular process of HDR is depicted in figure 25. Following
transfection of the CRISPR/Cas9 plasmid into P. berghei parasites and translation of the Cas9
endonuclease, a DSB occurs at a specific target sequence (TS) within tlap2 in the parasite
genomic DNA via the guide RNA (gRNA), which consists of the TS co-transcribed with an
RNA scaffold. The break in DSB initiates DNA repair in which the “homology repair template”
replaces the WT pbtlap2 gene, resulting in pbtlap2-KO.

Figure 25. Schematic Process for Gene Deletion of tlap2 in P. berghei. pBCTP2 gene-deletion
construct with left and right homologous arms act as a donor template to replace the Tlap-2 gene
region in the genome of the parasite. Following homologous recombination after a DSB in the
genome, the repair template consists of a short disrupter sequence (Dis) which replaces Tlap-2
following successful gene deletion. Gene deletion verification primers shown (P7-P10).
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Design and Generation of CRISPR/Cas9 Deletion Plasmid
As previously eluded to, I am using a template-based repair mechanism to achieve
deletion for the target gene. To achieve this, the Cas9 protein, which associates with the gRNA,
briefly induces a double stranded break in the DNA target sequence and then the homology
repair template repairs the DNA providing sequences from the 5’ and 3’ UTRs flanking the
target gene plus the small disrupter (Dis) sequence. The homology repair template will replace
the original (endogenous) pbtlap2 gene in the genome.
The CRISPR/Cas9 deletion plasmid previously generated in our lab was named pBCS
(plasmid for berghei containing Cas9 for Saxo KO) (Fig. 26). The plasmid consists of the
following major components: 1) strong constitutive P. berghei elongation factor 1 alpha
(Pbeef1α) promoter that drives expression of the CRISPR-associated protein 9 (Cas9), and 2) P.
berghei U6 (PbU6) small nuclear RNA promoter that drives the expression of the gRNA.
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Figure 26. Organization of pBCS Template Plasmid. pBCS contains the following components:
P. berghei U6 promoter (PbU6), CRISPR associated nuclease gene (Cas9), pyrimethamine
resistance gene (hDHFR), guide RNA scaffold (gRNA), P. berghei elongation factor 1α
promoter (Pbef1α)), to generate a deletion from only this single construct. Parts replaced with
pbtlap2 components highlighted in yellow boxes.
For generation of the CRISPR construct for pbtlap2, I performed a series of molecular
cloning steps to replace the pbsaxo targeting components with the pbtlap2 gene targeting
components. First, I aimed to replace the pbsaxo gRNA with the corresponding pbtlap2 gRNA.
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Thus, with the help of the ChopChop software (Labun et al., 2016, 2019 & Montague et al.,
2014), I selected an optimal target cut site within pbtlap2 in order to construct an optimal gRNA.
ChopChop was useful as it allowed us to screen for an optimal target site within the gene, while
minimizing the probability of off-site cutting events. Also, the software made sure to include the
required 3’ NGG sequence (protospacer adjacent motif = PAM) (Anders et al., 2014).
Subsequently, I designed primers (Table 2, P1 & P2) and then PCR amplified the pbtlap2 gRNA
sequence (Fig. 27).

Figure 27. Generation of guide RNA and Cloning into pBCS Template. A) gRNA amplicon
with NdeI and AatII restriction sites. The 20 bp target sequence is highlighted in yellow. B) The
pbtlap2 gRNA cassette was directionally cloned into the pGEM propagation vector and
sequenced before insertion into the pBCS CRISPR/Cas9 plasmid template.
After the first attempt to insert the gRNA amplified fragment into the pBCS template
construct, sequence verification indicated that in addition to the pbtlap2 gRNA, the pbsaxo
gRNA was still present in the construct. I conducted additional rounds of cloning and succeeded
in generating a construct that contains the pbtlap2 gRNA template only.
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Next, I generated the homologous repair template that contained a 5’ homology arm (5’
UTR) and 3’ homology arm (3’ UTR) both of which flank pbtlap2 upstream and downstream
within the genome (Fig. 28). The homology repair template also contains a disrupter sequence
which replaces the pbtlap2 gene following DSB and DNA repair. A generalized depiction of the
process of deleting the tlap2 gene via homology repair using the CRISPR plasmid containing the
homology repair template is shown below.

Figure 28. Organization of the pbtlap2 Genomic Region and Gene Deletion Following
Homology-Directed Repair . For generation of the pbtlap2 homology repair template, regions
upstream and downstream of the pbtlap2 coding sequence were used as the 5’ and 3’ homology
arms (referred to as 5’UTR and 3’UTR). The CRISPR target sequence as the specific location
for Cas9-mediated gene deletion is located near the 5’ end of the pbtlap2 gene (shown as red
lightning arrow). Disrupter sequence is located between each homology arm and replaces
pbtlap2 gene following repair. Entire PbWT genomic region around pbtlap2 consists of 2,638bp
and following gene deletion results in length of 1,114bp.
To generate the complete homology repair template, I first cloned the entire homology
repair template in the TOPO cloning vector, before cloning into the edited pBCS plasmid already
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containing the tlap2 gRNA region (Fig 29). The pbtlap2 5’UTR as well as the 3’UTR regions
were PCR amplified, respectively. The 5’UTR forward and reverse primers introduced a BamHI
restriction site and the 3’UTR primers introduced an XbaI restriction site to allow directional
cloning. The 5’UTR forward and 3’UTR reverse primers introduced HindIII sites which were
used to eventually excise the completed homology repair template and ligate into the edited
pBCS plasmid with gRNA, which completed generation of the pbtlap2 CRISPR/Cas9 plasmid
that was ultimately named pBCTP2 (plasmid for berghei containing Cas9 for Tlap2 KO).
Briefly, the 5’UTR fragment was inserted into the BamHI restriction site of a TOPO cloning
vector (Invitrogen) that was already cloned by a previous graduate student in our lab to include
the Dis sequence. The completed “TOPO/5’UTR/Dis” plasmid was then digested with XbaI to
open the plasmid for insertion of the 3’UTR amplified fragment. Note, the 3’UTR fragment was
separately generated in a different TOPO vector “TOPO/3’UTR”, and subsequently digested
with XbaI to release the fragment and insert it into the TOPO/5’UTR/Dis generated plasmid.
This completed the generation of the homology repair template in the TOPO vector. The
completed homology repair template (5’UTR/Dis/3’UTR) in TOPO was digested with HindIII
and ligated into the edited pBCS plasmid, to generate the final pBCTP2 plasmid. The completed
pBCTP2 plasmid was confirmed by sequencing.
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Figure 29. Generation of Homology Repair Template and Final pBCTP2 Construct. A) PCR
amplification of 5’UTR and 3’UTR regions of homology repair template using corresponding
restriction enzyme sites. B) Cloning of 5’UTR PCR amplified fragment into TOPO plasmid
containing gene disrupter sequence (Dis) at BamHI restriction enzyme site. Cloning of 3’UTR
PCR amplified fragment into different TOPO plasmid at XbaI restriction enzyme site. C)
Restriction digested the generated “TOPO/5’UTR/Dis” and “TOPO/3’UTR” plasmids using
XbaI enzyme and cloning of TOPO/3’UTR fragment into TOPO/5’UTR/Dis plasmid at XbaI
restriction enzyme site to complete generation of homology repair template. D) Restriction
digestion of generated TOPO plasmid containing the complete homology repair template at
HindIII restriction enzyme sites and cloning of repair region into final pBCS plasmid containing
the pbtlap2 TS/sgRNA cassette (pBCTP2). E) Plasmid map of pBCTP2 plasmid for
CRISPR/Cas9-mediated gene deletion of pbtlap2. pBCTP2 construct contains the homology
repair template region, target sequence (TS) and a short guide RNA (sgRNA), Cas9 gene,
Pbeef1a promoter, ampicillin resistance (AmpR), and pyrimethamine resistance (hDHFR). Map
generated using SnapGene software (GSL Biotech).
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Generation of a Transgenic P. berghei Parasite Line
To put CRISPR to work and generate P. berghei tlap2-KO parasites, I had to transfect the
pBCTP2 plasmid into P. berghei WT parasites. To accomplish this, parasites have to be grown in
mice, extracted from mouse blood, transfected with plasmid, and injected back into naïve mice
(Fig. 30). First, a naïve mouse was infected with P. berghei WT parasites. After the parasitemia
reached 10-15%, the parasites were harvested and transferred to 2-4 new naïve mice. Once the
parasitemia’s reached 1-3%, infected blood was extracted and placed in culture at 37C
overnight to allow maturation into schizonts. The schizonts were purified from culture using a
Nycodenz density gradient and then the parasites were transfected with the pBCTP2 plasmid via
electroporation. Unfortunately, I ran into many issues with successfully getting the schizonts to
purify properly in the Nycodenz. After many failed attempts, I concluded that the Nycodenz was
too far expired and thus was not working properly to separate the parasites out. This led to
multiple attempts at tail vein injecting parasites that were transfected with the plasmid, however,
I don’t believe many, if any, parasites were actually present during injections. Once I identified
this as a problem, our lab ordered fresh Nycodenz and when repeating the experiment, I
immediately noticed better results. I had now successfully separated the schizonts from the
overnight mouse RBC culture and was able to move onto transfections with pBCTP2.
The transfected parasites were immediately injected into seven naïve mice via the tail
vein. Using giemsa stained blood smears, I screened the injected mice daily for parasites. Once
parasites were observed, the antimalarial drug pyrimethamine was added to the mouse drinking
water to select for transgenic parasites. Pyrimethamine resistant parasites were observed in the
infected mice between 7-15 days post infection. I monitored the parasitemia of each mouse
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until it reached the highest possible level (~15%), at which the mice were exsanguinated.
Infected blood from each mouse was collected and parasite genomic DNA was extracted for
PCR verification of pbtlap2-KO.

Figure 30. Generation of Transgenic Parasites. A) Infected mouse blood collected and cultured
overnight at 37°C and 5% CO2 to obtain mature schizonts. B) Schizonts purified from culture
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using a 17% nycodenz solution gradient. Blood smear to confirm quality of purified schizonts.
C) Electroporation transfection of schizonts with pBCTP2 using Amaxa Nucleofector II. D) Tail
vein inject mice with transgenic parasites.
Verification of pbtlap2 Gene Deletion Shows Conflicting Results
To verify either pbtlap2-KO or PbWT (unsuccessful deletion), I designed specific
reporter primers (P7 and P8) and utilized other primers our lab already had available (P9 & P10),
as shown in Table 2 and Figure 25. Parasite genomic DNA previously isolated following
transfection and drug selection was used for verification analysis. It is important to point out that
I ran into issues with obtaining optimal concentrations of extracted parasite genomic DNA
during the purification step. Thus, low concentrations (<10ng/uL) of genomic DNA template
may have contributed to issues when PCR amplifying for verification of successful gene
deletion.
Because drug resistant parasites were observed in mouse 3 (M3), mouse 6 (M6), and
mouse 7 (M7) before the other infected mice (M1, M2, M4, M5), I began gene deletion
verification in M3, M6, and M7 first. To amplify the pbtlap2 locus, primers P7 and P8 were
used as their complementary binding site in the genome is located outside the pbtlap2 UTRs.
Thus, these primers bind to the genomic DNA of WT parasites as well as KO parasites, resulting
in a shorter band for the latter. The expected PCR amplicon size for P. berghei WT genomic
DNA was ~2.6 kb, while the expected size for successful KO was ~1.1 kb. I also used primer P9
and P10 which were complementary to sequences in the disrupter portion of the pBCTP2
plasmid (see Fig. 25). Initial verification of parasite genomic DNA from M3, M6, and M7
indicated unsuccessful amplification in all samples (Fig. 31). The only sample that amplified
following PCR was the PbWT control.
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Figure 31. Initial pbtlap2 Gene Deletion Verification Indicated Unsuccessful Amplification in
Experimental Samples. Three PCR primer sets (P7 & P8), (P7 & P10), and (P8 & P9) were used
to detect whether gene deletion occurred in three mice (M3, M6, M7) infected following
pBCTP2 transfection. DNA templates used were: PbWT genomic DNA, and DNA extracted
from M3, M6, and M7 following transfection and drug selection. Red arrow indicated the band
corresponding to expected PbWT amplicon.
Surprisingly, when repeating the PCR verification with the same genomic DNA samples,
I observed an ~2.6kb DNA band in M3 and M7, indicating PbWT and no successful gene
deletion (Fig. 32). There were smaller amplified bands also present, however, it is unclear what
they represent. I did not observe any PCR amplification in M6.
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Figure 32. Additional pbtlap2 Gene Deletion Verification Indicated Only PbWT Amplification
in Experimental Samples. PCR primers P7 & P8 were used to detect whether gene deletion
occurred in three mice (M3, M6, M7) infected following pBCTP2 transfection. DNA templates
used were: PbWT genomic DNA, and DNA extracted from M3, M6, and M7 following
transfection and drug selection. Red arrows indicate the bands corresponding to expected PbWT
amplicon and an unknown small band.
After performing additional blood smears of the other mice (M1, M2, M4, M5), I noticed
that all mice now showed drug resistant parasites. Thus, I performed an initial PCR verification
of the parasite genomic DNA extracted from each of these mice using primers P7 and P8 (Fig.
33). Unfortunately, I only observed successful PCR amplification in the PbWT sample, similar
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to the earlier PCR verification. The formation of primer-dimers (PD) were observed in some of
the samples.

Figure 33. Additional pbtlap2 Gene Deletion Verification Indicated Unsuccessful Amplification
in Experimental Samples. PCR primers P7 & P8 were used to detect whether gene deletion
occurred in four mice (M1, M2, M4, and M5) infected following pBCTP2 transfection. DNA
templates used were: PbWT genomic DNA, and DNA extracted from M1, M2, M4, and M5
following transfection and drug selection. Red arrow corresponds to band corresponding to
expected PbWT amplicon and primer-dimers (PD).
I continued to analyze the parasite genomic DNA for possible pbtlap2 gene deletion.
Thus, I performed another PCR amplification of M3, M6, and M7 using primers P7-P10.
Interestingly, I now observed a 1.1kb DNA band in M3, indicating successful pbtlap2 gene
deletion (Fig. 34).
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Figure 34. Additional pbtlap2 Gene Deletion Verification Indicated Successful KO in M3. Two
PCR primers sets (P7 & P10) and (P8 & P9) were used to detect whether gene deletion occurred
in three different mice (M1, M2, M3) infected following pBCTP2 transfection. DNA templates
used were: PbWT genomic DNA, and DNA extracted from M1, M2, and M3 following
transfection and drug selection. Red arrow indicated the band corresponding to a successful
pbtlap2 gene deletion.
With the conflicting results as to whether the pbtlap2 gene was successfully deleted in the
genomes of the parasites extracted from infected mice, it was apparent that further investigation
was necessary before moving forward with a successful KO parasite line. Considering that the
volume of frozen down infected blood stock was limited, I attempted to re-infect naïve mice with
containing the pyrimethamine resistant parasites, however, was unsuccessful. I could not get
naïve mice to become infected with the parasites. Due to time constraints, I then shifted the
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focus of my thesis work back to the human cancer cell heterologous expression work at this
point. Soon, our lab will again attempt to produce pbtlap2 gene deletion parasites for
downstream phenotypic analysis of loss of the gene.

CHAPTER IV
DISCUSSION
The purpose of this thesis was to investigate the novel, putative MAP, PbTLAP2, and to
determine whether it binds to and/or stabilizes microtubules, thus identifying it as a structural
MAP. This could suggest a potential role in regulation of microtubules in the protozoan parasite
P. berghei, the causative agent of Malaria. Prior to this study, there have been no investigations
into structural MAPs in any Plasmodium species. Previous studies of Plasmodium proteins that
interact with microtubules focused on motor proteins, such as kinesin and dynein (Fowler et al.,
2001). To investigate the microtubule-binding properties of my candidate protein, I generated
multiple reporter plasmids to overexpress PbTLAP2 in human cancer cell lines and analyze its
subcellular localization. I also investigated subcellular localization of PbSAXO, a protein
previous lab members have been working on, and several control proteins. Protein localization
was investigated using immunofluorescence labeling (IF) coupled to laser scanning confocal
microscopy. My findings strongly suggest that PbTLAP2, as well as PbSAXO, bind to
microtubules in the human cancer cell line. Furthermore, I established that the conserved Cterminus of PbTLAP2 (amino acids 347-597) are sufficient to bind microtubules, also
confirming the presence of the microtubule-binding domain in this region. Finally, I observed
PbTLAP2 and PbSAXO to likely stabilize microtubules against cold treatment, but not against
the microtubule-destabilizing drug nocodazole. In parallel, I generated a CRISPR/Cas9 gene
deletion construct for pbtlap2. This will be used in the future to generate a TLAP2-knockout
98
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(KO) line of P. berghei parasites for analysis of potential malformations of the microtubules in
the absence of the TLAP2 protein.
As a first-hand approach, I used a human cancer cell system consisting of U-2 OS cells to
study the subcellular localization of PbTLAP2. Studying PbTLAP2 in the parasite is more
challenging due to its small size as well as the unique location and function of the microtubules
within the parasite. For reference, the Plasmodium ookinete is ~2µm long and ~500nm wide,
while in comparison U-2 OS cells used in this work can span up to 100µm, making their
microtubule cytoskeletal more expansive and easier to identify. Thus, using U-2 OS cells for
this work allowed for efficient visualization of the MAPs’ interactions with the mammalian cell
microtubules. Moreover, the high sequence and structural conservation of the tubulin proteins
between human and protozoa has allowed researchers to study microtubule interactions of
protozoan parasite MAPs in human cancer cell lines as shown previously (Liu et al., 2013 &
2016; Dacheux et al., 2012).
Initially, I began my studies into pbtlap2 by generating a CRISPR/Cas9 gene deletion
plasmid to generate TLAP2-KO parasite lines. However, due to time constraints, I moved my
investigations to study PbTLAP2 microtubule-binding in human cancer cell lines. The first
expression plasmid that I generated and transfected into U-2 OS cells was pcDNA3.1-mEmeraldPbTlap2-FL, which subsequently expressed full length (FL) PbTLAP2 tagged with N-terminal
mEmerald. Based on my results, I showed that the mEmerald-PbTLAP2-FL fusion protein
displays a diffuse cytosolic distribution in U-2 OS cells, indicating that the fusion protein does
not bind to microtubules in these cells. This finding is inconsistent with the data from the
researchers studying the TgTLAP2 homolog, who showed that mEmerald-TgTLAP2 binds and
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bundles microtubules in HeLa cells and in Toxoplasma (Liu et al., 2016). Considering that both
HeLa cells and U-2 OS cells are human cell lines containing the same microtubules, I would not
expect that this difference in cell lines would be the reason why mEmerald-PbTLAP2-FL did not
bind to the U-2 OS microtubules. Rather, I hypothesized that the mEmerald-PbTLAP2-FL does
not bind to the microtubules because the relatively large size of the mEmerald tag interferes with
the protein’s ability to bind to microtubules. The mEmerald protein consists of 240 aa’s, while
the full length PbTLAP2 protein consists of 598 aa’s. Thus, mEmerald is about 40% the size of
PbTLAP2, which is quite significant. However, I proved my hypothesis incorrect by later
showing that by using a small Myc tag (10 aa’s), rather than the mEmerald tag, PbTLAP2 could
bind to microtubules. It is intriguing why the TgTLAP2 protein does not exhibit this issue ofnot
binding microtubules when it is also expressed with an N-terminal mEmerald tag in Toxoplasma
or human cancer cell lines. It would be interesting to fuse TgTLAP2 with a Myc tag to see
whether the protein has different and perhaps better binding to microtubules. Alternatively, I also
hypothesized that perhaps there is a problem with the translation of the mEmerald-PbTLAP2-FL
protein in cells due to the general AT-richness of the P. berghei genome. However, this
hypothesis was also proved to be incorrect based on my later findings that the proteins binds to
microtubules with a different tag present.
I found that Nterm mEmerald-PbSAXO also showed a cytosolic distribution in
transfected cells and that transfection of the plasmid into the U-2 OS cells resulted in a low
transfection efficiency (31%). It is important to mention, however, that the TgTLAP2 control
plasmid transfection also resulted in low transfection efficiency (34%). Interestingly, several
repeat transfections and expression of the N-terminally tagged mEmerald-PbTLAP2-FL protein
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also consistently resulted in a low transfection efficiency (<20%). This was all surprising
considering that the manufacturer’s protocol projected efficiencies of 75% or greater. The
reason behind the low transfection efficiencies is not clear. To look into this further, we can first
test other transfection kits and/or transfection methods to study any differences in transfection
efficiency and expression of the fusion proteins. It may also be worthwhile to try using a
different starting plasmid to transfect into cells and express the proteins.
Following the approach of Liu et al 2016 methods in which the researchers expressed
only the Cterm 276 aa’s of TgTLAP2 in cells to test for microtubule binding, I next expressed
mEmerald-PbTlap2Δ in cells, containing only the Cterm 250 aa’s of the protein. My findings
showed that Emerald-PbTlap2Δ displayed a diffuse cytosolic distribution in the cytosol, similar
to that of mEmerald-PbTlap2-FL. This indicates that mEmerald-PbTlap2Δ also does not bind to
microtubules. My finding was inconsistent with published results, in which the researchers
found that the Cterm 276 amino acids of TgTLAP2 bind to and bundle microtubules in HeLa
cells and in the Toxoplasma parasite (Liu et al., 2016). In fact, both the full length and truncated
(Nterm 276 aa’s) version of the mEmerald-TgTLAP2 fusion protein did not appear to have any
issues interacting with microtubules in the cells. One possible explanation for why mEmeraldTgTLAP2 full length or truncated binds to microtubules, but mEmerald-PbTLAP2Δ does not, is
that both homologs are still very different, even though they share some conservation in their
Cterm regions. This is especially so given that the Nterm regions of each homolog are very
different and we do not yet know what functions they may serve, if at all. Thus, perhaps
structural differences between TgTLAP2 and PbTLAP2 are the reason why only mEmeraldTgTLAP2 binds. In terms of the transfection efficiencies for each plasmid, the transfection
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efficiency of the pC22-mEmerald-PbTlap2Δ plasmid was as low (~15%) as that of the pC22mEmerald-PbTlap2-FL plasmid.
Similarly, adding the GFP tag – which is a slightly less refined tag compared to
mEmerald – to the C-terminus of PbTLAP2-FL and/or PbTLAP2Δ showed similar results for the
transfection efficiencies and subcellular localization of the fusion proteins compared to when the
proteins were tagged with Nterm mEmerald. I show that C-terminal tagged PbTLAP2Δ-GFP
displayed a diffuse cytosolic distribution throughout the cytosol of expressing cells and exhibited
a low transfection efficiency (19%). This was not entirely surprising to me given that C-terminal
GFP tag was now much closer to the assumed microtubule-binding domain of PbTLAP2,
compared to when it was tagged with N-terminal mEmerald. With the C-terminal GFP tag being
so close to the binding domain, there would be a greater chance that the tag would get in the way
of allowing PbTLAP2 to interact with microtubules. Interestingly, the C-terminal tagged
PbTLAP2-FL-GFP fusion protein did not express properly in cells. Rather, I observed a
punctate fluorescence pattern along the perimeter of cells, close to the location of the plasma
membrane. However, I hypothesize this to be an artifact because the fluorescence I was
observing was likely not the expressed fusion protein. Because I could not find any cells that
appeared to even show a diffuse cytosolic distribution of PbTLAP2-FL-GFP, I concluded that
the fusion protein does not express in transfected cells. The reason behind this is not clear since
the full length fusion protein with the N-terminal Emerald tag did show expression in cells, albeit
no binding to microtubules. Further investigations into this may be useful in the near future. I
observed similar results when transfecting the PbSAXO-GFP Cterm plasmids in cells and I did
not observe any apparent microtubule-binding.
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At this point, I observed issues with the transfection rate and the lack of microtubulebinding of PbTLAP2 whether I transfected the protein as full length or the truncated version, in
addition to whether the GFP tag was at the Nterm or Cterm end (Fig 35). A possible explanation
for these results is that the size of the GFP tags are simply too large and are affecting the ability
of the PbTLAP2 to bind to microtubules in U-2 OS cells. The tag may in fact be causing
hindrance in the ability of PbTLAP2 to bind to microtubules. Potentially, the GFP tag becomes
positioned in such a way that it blocks access of the microtubule-binding domain in PbTLAP2 to
microtubules. When closely reviewing the Dacheux paper on microtubule binding and stabilization by the MAP TbSAXO (Dacheux et al., 2012), I noticed that the researchers only
show images of the TbSAXO interacting with microtubules when the protein is fused with a Myc
tag, which is just 10 AA short and much smaller than the GFP tags. Although they did not
publish images in which TbSAXO was tagged with GFP, they did however tag the human SAXO
(hSaxo) homolog with GFP and showed binding of the MAP to microtubules, which is
interesting. Considering the issues that I have thus far encountered when using the GFP tags, I
decided to test whether expressing PbTLAP2 with the smaller Myc tag, instead of a GFP tag,
would allow PbTLAP2 to interact with microtubules.
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Figure 35. Schematic representation of PbTLAP2 with various GFP tag alterations and lack of
binding to microtubules. Both N-terminal and C-terminal GFP tagged PbTLAP2 (full length
gene and truncated version) are not able to bind to microtubules.
For the first time, I supported my hypothesis by showing that PbTLAP2 functions as a
microtubule-binding protein based on the fact that when tagged with Myc, the fusion protein
localizes to microtubules in U-2 OS cells. Furthermore, I showed that both PbTLAP2-FL and
PbTLAP2Δ tagged with C-terminal Myc localize to microtubules in U-2 OS cells. A schematic
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representation of the Myc microtubule-binding is provided for reference (Fig. 36). I also showed
for the first time that PbSAXO-Myc binds to microtubules in U-2 OS cells as well. Both of
these findings were consistent with the results of the expression of TbSAXO-Myc in U-2 OS
cells, which also showed binding to microtubules. This was in line with the results that
researchers previously showed where TbSAXO-Myc showed microtubule-binding and -bundling
in U-2 OS cells (Dacheux et al., 2012). Surprisingly, in stark contrast to the previous GFP
plasmid transfections, I observed a high transfection efficiency (>90%) for all plasmid
transfections. With my new findings, I concluded that it is likely that GFP was the cause of the
poor transfections and no microtubule-binding in the previous experiments.

Figure 36. Schematic representation of PbTLAP2 with C-terminal Myc tag binding to
microtubules. Both C-terminal Myc tagged PbTLAP2-FL and PbTLAP2Δ bind to microtubules.
Now that I had showed that PbTLAP2 functions in binding to microtubules, I next
wanted to test whether the protein also functions to stabilize microtubules. Considering
Plasmodium experiences a significant drop in temperature during the mosquito stages, I became
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curious about this interesting factor and whether PbTLAP2 may have a role in cold stabilizing
the parasite subpellicular microtubules during this time of stress. The specialized subpellicular
microtubules found in protozoan parasites, such as Plasmodium, Toxoplasma, and Trypanosoma,
require significant regulation by a variety of different MAPs (Liu et al., 2016). Mammalian
cells, on the other hand, do not contain subpellicular microtubules and thus may not require as
strict of microtubule regulation by MAPs as the protozoan parasites do.
In T. brucei, the TbSAXO MAP stabilizes subpellicular microtubules in the parasite by
conferring cold-resistance (Dacheux et al., 2012). Noteworthy, T. brucei is a flagellated parasite
and Plasmodium spp. also contain flagella; however, only in the male gametocytes, which
undergo exflagellation. Without the stabilization of the flagella in the gametocytes, the ookinete
would not properly develop and successful transmission of the parasite would not take place.
Also, similar to the way Plasmodium experiences a temperature drop in the mosquito,
Trypanosoma parasites experience a temperature drop in the Teste fly insect host (Engstler &
Boshart, 2004). This suggests that each protozoan parasite requires certain structural MAPs,
such as TLAP2 and/or SAXO possibly, for stabilization of the subpellicular microtubules in the
cold life stages. Thus, it is possible that the PbSAXO homolog, or potentially PbTLAP2, may be
functioning in a similar way to TbSAXO in cold-stabilizing microtubules in the parasite.
Curiously, the Toxoplasma parasite does not have an insect vector, like Plasmodium and
Trypanosoma, and therefore it is possible that the conditions controlling microtubule regulation
in Toxoplasma may be different. Thus, it could be that the subpellicular microtubules in
Plasmodium or Trypanosoma have a higher dependence on regulation by MAPs to provide
stabilization in the cold insect stages.
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Supporting my hypothesis that PbTLAP2 stabilizes microtubules, I found that only
PbTLAP2Δ-Myc showed some stabilization of microtubules in U-2 OS cells at 4°C. The exact
reasoning why only PbTLAP2Δ-Myc, and not the full length protein, stabilized microtubules
against cold is not known. However, this new finding that PbTLAP2 cold-stabilizes
microtubules could suggest that PbTLAP2 does have a major role in stabilizing Plasmodium
subpellicular microtubules, especially in the colder mosquito stages. Further work in our lab is
needed to confirm that PbTLAP2 is indeed cold-stabilizing microtubules in human cells, as well
as more importantly in the P. berghei parasite, especially considering only PbTLAP2Δ showed
stabilization and the full length form of the MAP did not. In summary, it appears that PbTLAP2
has microtubule stabilization properties against cold.
Prior research showed that pbtlap2 expression is upregulated in the ookinete and
gametocyte stages of the parasite (Hoeijmakers et al., 2014). This is interesting given that the
subpellicular microtubules are critically important for maintaining parasite structure in the
mosquito stages, where the ookinete and gametocytes are present. Because I show that
PbTLAP2 has potential microtubule stabilization mechanisms against cold, this further supports
my hypothesis that PbTLAP2 plays an important role in regulating the subpellicular
microtubules during the mosquito stages of development. In addition, because I showed that
PbSAXO also has microtubule cold-stabilization properties, this could suggest PbSAXO also
stabilizes the subpellicular microtubules in the mosquito stages. Further work is necessary to
determine if PbTLAP2 and PbSAXO have a similar or different mechanism for cold-stabilizing
microtubules.
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Further investigating the microtubule-stabilization abilities of PbTLAP2, I did not
observe any microtubule-stabilization in cells treated with nocodazole and expressing PbTLAP2FL or PbTLAP2Δ. The appearance of the cells following nocodazole treatment did look
different than they did following cold treatment. It looked as though the microtubules had
completely depolymerized following nocodazole treatment, but only partially depolymerized
following cold treatment. Being that nocodazole binds to free-tubulin in cells, it makes sense
that I would observe complete destabilization of microtubules. However, the exact mechanism
that cold has on destabilizing microtubules is unknown. Therefore, future investigations would
be necessary to investigate in-depth the reasoning behind the difference I observed following
either treatment. It is interesting to consider the fact that Plasmodium is not naturally exposed to
nocodazole, however, is exposed to cold conditions. Thus, it makes sense that either PbTLAP2
would cold-stabilize microtubules in the parasite, but not nocodazole-stabilize microtubules as
the parasite does not normally come in contact with this drug.
A previous graduate student in our lab generated trxl1- and saxo-KO P. berghei parasites
and showed that trxl1 is not essential in the asexual blood stages and that there is no resulting
phenotype in KO asexual blood stage parasites (Kiernan et al., 2017). However, trxl1-KO did
affect the morphology of the ookinete structure in the mosquito. In addition, it was found that
saxo is also not essential in the asexual stages, but that there may be some issues with
gametocyte survival and schizont development. The T. gondii researchers showed that tgtrxl1,
tgspm1, and tgtlap2 may all have compensatory mechanisms between each other when
regulating the microtubule cytoskeleton (Liu et al., 2013 & 2016). In addition, it is possible that
each of these MAPs are complexing with each other and binding to microtubules to provide a
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collective regulation mechanism. Thus, a next step for our lab would be to not only generate the
pbtlap2-KO parasites, but also to generate parasites with multiple gene KO’s, including pbsaxo
and pbtlap2, as well as pbtrxl1, pbsaxo, and pbtlap2. This would allow us to determine whether
there are compensatory mechanisms at play and if the parasite microtubule cytoskeleton is
further affected by loss of multiple genes. To test this, it would first be important to generate the
P. berghei tlap2 gene deletion parasites and analyze the resulting phenotype in the mosquito
stages. With the loss of tlap2, we would predict that the microtubules of the parasite might
depolymerize; however, if there are other stabilizing MAPs present, they may have
compensation functions for the loss of TLAP2 expression.
For the CRISPR/Cas9 gene deletion studies, I was not yet able to generate a population of
pbtlap2 deletion parasites; however, I successfully transfected schizonts with the CRISPR
plasmid and observed some parasites to have pbtlap2 KO via PCR verification. Unfortunately,
the PCR verifications showed WT parasites lacking gene deletion, in addition to some parasites
with a KO when analyzing the purified parasite genomic DNA of infected mice. Due to the
mixed results that I observed during gene deletion verification, repeat transfections are necessary
to generate new pbtlap2-KO parasites so that we can perform phenotypic analysis of the
resulting parasites.
Interestingly, a previous deletion of the tlap2 gene in both P. berghei and P. falciparum
showed that there was no abnormal phenotype in the blood stages of the mutant parasites
(Bushell et al., 2017). However, the sexual mosquito stages were not examined following tlap2KO, thus our lab could potentially fill this knowledge gap in the near future. Considering I
showed that PbTLAP2 likely stabilizes microtubules against cold, and that the parasite
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encounters a temperature drop in the mosquito stages, we are curious whether the tlap2-KO
parasites would show a malformed microtubule cytoskeleton in the mosquito stages. In addition
to the generation of only pbtlap2 KO parasites, it would be interesting to generate a double KO,
consisting of Δpbtlap2Δpbsaxo parasite line, to analyze the resulting microtubule structures
following cold treatment with no expression of either MAP. Investigating only tlap2 KO or only
saxo KO parasites, or when both genes are knocked-out together would also elucidate whether
there is compensation between the MAPs.
Although this thesis focuses on the tlap2 gene, it is important to point out that
Plasmodium, contains other uncharacterized tlap homologues, such as tlap1 and tlap3.
Compared to tlap2, there is little information available on the tlap1 and tlap3 genes on the
PlasmoDB and ToxoDB databases. The majority of the information available for the tlap2 genes
pertains to the tlap2 gene. Although researchers showed in investigations into TLAP1 of the
related parasite Toxoplasma gondii that the MAP localizes to the subpellicular microtubules,
further studies are needed to determine whether TgTLAP1 plays a significant role in microtubule
regulation (Liu et al., 2013). Investigations by these authors into the TgTLAP3 showed that it
localizes to specific microtubule regions in Toxoplasma. Liu et al 2016 described TgTLAP2 as
having the most profound impact on the regulation of the T. gondii microtubule cytoskeleton.
The MAP not only co-localizes with microtubules in both HeLa cells and the T. gondii parasite,
but also bundles microtubules in HeLa cells. The overexpression of TgTLAP2 in Toxoplasma
causes a major malformation of the microtubules. They also performed initial investigations
into the TLAP2 homolog of the human malaria parasite Plasmodium falciparum (PfTLAP2-a).
They found that PfTLAP2 tagged with N-terminal mEmerald and expressed in T. gondii
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localizes to the apical region of the parasite. This suggested that PfTLAP2 may bind to
microtubules, but further investigations were required to confirm this.
It is important to note that the different genes and protein products mentioned in this
work are from very different species. This could certainly lead to different functions of the
different proteins across Plasmodium, Toxoplasma, and Trypanosoma parasites. For example,
the major flagellum structure found in Trypanosoma is not found in either Plasmodium or
Toxoplamsa. In addition, Toxoplasma is in an entirely different genus than Plasmodium. So,
although I make many comparisons of the different MAPs across these organisms, it is critical
that I account for the fact that they are not the same proteins or organismal species that produce
them. In addition, it is important to consider that although microtubules within each organisms
are highly conserved, the MAPs produced in each organisms are likely unique and have unique
functions for the specific organism.
With this study, I am the first to provide new information on the function of the TLAP2
protein in the Plasmodium malaria parasite and the structural regulation of the Plasmodium
microtubule cytoskeleton. Prior to this study, little research has focused on the basic biology of
the Plasmodium parasite. In addition, there have been no prior studies of the TLAP2 protein in
any Plasmodium species. Based on the results shown here, I support my hypothesis that
PbTLAP2 binds to microtubules and likely has some microtubule stabilization properties. My
results suggest that TLAP2 could play a role in regulating and stabilizing the microtubule
cytoskeleton in the Plasmodium parasite. Thus, our next steps would be to investigate the
expression, localization, and potential stabilization properties of the protein directly in the P.
berghei parasite. Overall, this study contributes to our fundamental understanding of
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Plasmodium parasite structural MAPs and their regulation of microtubules. As the parasite
cytoskeleton has been a continual target for potential drug interventions, this work also has the
potential to shed light on possible new disease intervention methods in Plasmodium.

APPENDIX A
GENERATED Pbtlap2 AND Pbsaxo EXPRESSION PLASMIDS
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TABLE OF ALL GENERATED EXPRESSION PLASMIDS
Appendix A
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APPENDIX B
ALIGNMENT OF C-TERMINAL Tgtlap2, Pbtlap2, and Pftap2 PROTEINS
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CLUSTAL OMEGA ALIGNMENT OF N-TERMINAL PROTEIN REGIONS
Appendix B. Clustal omega alignment of N-terminal T. gondii TLAP2 (1-180aa), P. berghei
TLAP2 (1-346), and P. falciparum TLAP2 (1-281aa). (* = identical aa), : = highly similar aa, . =
similar aa).
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APPENDIX C
ALIGNMENT OF N-TERMINAL TgTLAP2, PbTLAP2, and PfTLAP2 PROTEINS
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CLUSTAL OMEGA ALIGNMENT OF N-TERMINAL PROTEIN REGIONS
Appendix C. Clustal omega alignment of N-terminal T. gondii TLAP2 (1-180aa), P. berghei
TLAP2 (1-346), and P. falciparum TLAP2 (1-281aa). (* = identical aa), : = highly similar aa, . =
similar aa).
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APPENDIX D
SEQUENCE ALIGNMENT OF HUMAN AND P. berghei ALPHA TUBULIN SUBUNITS
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CLUSTAL OMEGA ALIGNMENT OF TUBULINS
Appendix D. Human alpha 1A chain (Acc. Q71U36), P. berghei alpha tubulin 1 (PlasmoDB ID
PBANKA_0417700), and P. berghei alpha tubulin 2 (PlasmoDB ID PBANKA_0522700).
Amino acid (aa) sequence identities are 83%. (* = identical aa), : = highly similar aa, . = similar
aa).
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APPENDIX E
SEQUENCE ALIGNMENT OF HUMAN AND P. berghei BETA TUBULIN SUBUNITS
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CLUSTAL OMEGA ALIGNMENT OF TUBULINS
Appendix E. Clustal omega alignment of human beta chain (Acc. P07437) and P. berghei beta
tubulin (PlasmoDB ID PBANKA_1206900). The amino acid (aa) sequence identities between
the human and Plasmodium sequences are 88%. (* = identical aa), : = highly similar aa, . =
similar aa).
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APPENDIX F
TABLE OF EXPRESSION PLASMID TRANSFECTION RESULTS
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EXPRESSION PLASMID DETAILS AND TRANSFECTION RESULTS
Appendix F
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